Page last updated: 2024-08-18

pyrroles and Disease Exacerbation

pyrroles has been researched along with Disease Exacerbation in 393 studies

Research

Studies (393)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (0.51)	18.2507
2000's	115 (29.26)	29.6817
2010's	266 (67.68)	24.3611
2020's	10 (2.54)	2.80

Authors

Authors	Studies
Bora, V; Goyal, RK; Johar, K; Patel, BM; Patel, D	1
Buesch, K; de Zárate, IBO; Ferizovic, N; Jiang, J; Landfeldt, E; Summers, J; Werner, C	1
Sidaway, P	1
Andrews, J; Bowes, MA; Chapman, D; Conaghan, PG; Guillard, G; Koenig, A; Stein, A; Troum, O; Wilkinson, B; Xie, Z; Østergaard, M	1
Atas, N; Babaoglu, H; Salman, R; Satis, H; Tufan, A; Varan, O	1
Kato, F; Kurosaka, D; Oto, Y; Takahashi, Y	1
Ikeda, Y; Ikeuchi, M; Nakayama, Y; Saito, Y; Yamagishi, A; Yuki, R	1
Chen, HY; Chen, J; Diamantidis, CJ; Doerfler, RM; Fink, JC; Rahman, M; Ricardo, AC; Sondheimer, J; Strauss, L; Wagner, LA; Weir, MR; Xie, D; Zhan, M	1
Bai, X; Chi, Z; Cui, C; Dai, J; Ding, L; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X; Zhou, L	1
Andersen, A; Andersen, S; Axelsen, JB; Bogaard, HJ; da Silva Goncalves Bos, D; de Man, FS; Gomez-Puerto, MC; Goumans, MJ; Kurakula, K; Pan, X; Peters, EL; Schalij, I; Schiepers, REJ; Sun, XQ; Szulcek, R; van der Laarse, WJ; Vonk Noordegraaf, A	1
Bahl, A; Birtle, AJ; Crabb, SJ; Downs, N; Dunkley, D; Elliott, T; Griffiths, G; Jagdev, S; Jones, RJ; Khoo, V; Kumar, S; Light, M; Martin, K; Marwood, E; Northey, J; Robinson, A; Rooney, C; Salinas-Souza, C; Shaw, E; Stephens, C; Sundar, S; Westbury, C; Whitehead, A; Wilding, S	1
Fang, Q; Liu, P; Ma, D; Ni, M; Pan, C; Wang, J; Zhang, S	1
Bauer, S; Brahmi, M; George, S; He, K; Heinrich, MC; Hew, P; Hohenberger, P; Jones, RL; Kang, YK; Mir, O; Newberry, K; Pantaleo, MA; Patel, S; Roche, M; Rutkowski, P; Schöffski, P; Shen, L; Tap, WD; Trent, J; Villalobos, V; von Mehren, M; Zhou, Y	1
Chen, H; Li, H; Liu, C; Qian, B; Yao, Y; Zhang, J	1
Amano, K; Iwata, K; Kubo, S; Nagano, S; Nagasawa, H; Suematsu, E; Tanaka, Y; Tohma, S; Yamaoka, K	1
Dong, Z; Gao, J; Gong, J; Li, J; Li, Y; Shen, L	1
Chen, L; He, L; Lan, T; Pei, H; Tang, M; Zhang, C	1
Bjarnason, GA; Raphael, J; Thawer, A	1
Duplomb, S; Errihani, H; Layachi, M; Raiss, H; Tartas, S	1
Bananis, E; Burmester, GR; Charles-Schoeman, C; Connell, CA; Fan, H; Fleischmann, R; Kwok, K; Nash, P; van der Heijde, D; Zerbini, CAF	1
Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E	1
Pandey, M; Ramasamy, M; Shukla, M	1
Banon-Maneus, E; Brunet, M; Campistol, JM; Cucchiari, D; Diekmann, F; Hierro-Garcia, N; Lazo-Rodríguez, M; Moya-Rull, D; Oppenheimer, F; Piñeiro, GJ; Ramírez-Bajo, MJ; Revuelta, I; Rovira, J; Tubita, V; Ventura-Aguiar, P	1
Chapman, D; DeMasi, R; Fallon, L; Keystone, E; Lee, EB; van Vollenhoven, RF; Wilkinson, B; Zwillich, SH	1
Baraliakos, X; Deodhar, A; Fleishaker, D; Hendrikx, T; Kanik, KS; Li, D; Maksymowych, WP; Sherlock, SP; van der Heijde, D	1
Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX	1
Almeida, VH; Berzoti-Coelho, MG; Borges, CS; Cacemiro, MDC; Castro, FA; Ferreira, AF; Figueiredo-Pontes, LL; Gomes, FG; Monteiro, RQ; Nunes, NS; Simões, BP	1
Barata, PC; Cooney, M; Dreicer, R; Garcia, JA; Gupta, R; Mendiratta, P	1
Appleyard, CB; Flores, I; Rivera-Lopez, LL; Torres-Reverón, A	1
Fallon, L; FitzGerald, O; Gladman, DD; Graham, D; Kavanaugh, A; van der Heijde, D; Wang, C	1
Carman, BL; Machado, R; Predescu, DN; Predescu, SA	1
Almon, RR; DuBois, DC; Jusko, WJ; Song, D; Yu, R	1
Barone, C; Basso, M; Biolato, M; Castaldi, P; De Gaetano, AM; Grieco, A; Iaculli, A; Leccisotti, L; Miele, L; Pompili, M; Riccardi, L; Rufini, V	1
Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; Levy, D; McCurdy, DK; Mieszkalski, KL; Punaro, L; Reed, AM; Sandborg, CI; Schanberg, LE; Sherry, DD; Silver, RM; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E	1
Lee, CW; Park, SJ	1
Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J	1
Ba-Ssalamah, A; Bareck, E; Brodowicz, T; Eisterer, W; Häfner, M; Högenauer, C; Kastner, U; Kühr, T; Längle, F; Liegl-Atzwanger, B; Ploner, F; Schoppmann, SF; Widmann, G; Wrba, F; Zacherl, J	1
Ding, M; He, W; Jin, J; Wu, H; Xu, M; Yang, X; Yuchi, M	1
Cox, ME; Fazli, L; Ghaffari, M; Gleave, ME; Ibuki, N; Iu, I; Kashiwagi, M; Nakanishi, O; Pandey, M; Tojo, H	1
An, H; Hu, X; Lin, Z; Liu, H; Liu, L; Liu, Y; Lv, T; Xu, J; Xu, L; Yin, H; Zhang, H; Zhang, J; Zhu, Y	1
Ballet, S; Bini, J; Corot, C; Dickson, SD; Fayad, ZA; Izquierdo-Garcia, D; Klink, A; Lancelot, E; Mateo de Castro, J; Millon, A; Robert, P	1
Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J	1
Bracci, R; Cascinu, S; Maccaroni, E	1
Baxa, J; Boudová, L; Eberlová, L; Houdek, K; Kobr, J; Kočová, J; Křížková, V; Liška, V; Moláček, J; Nedorost, L; Tolinger, P; Tonar, Z; Třeška, V; Witter, K	1
Dadjou, Y; Panahi, Y; Pishgoo, B; Rakhshankhah, AS; Sahebkar, A; Taghipour, HR	1
Brugarolas, J; Jacobs, C; Kim, DW; Pedrosa, I; Straka, C; Timmerman, RD	1
Francois, R; Hochwald, SN; Iyer, R; Seshadri, M; Zajac-Kaye, M; Zhang, J	1
Choi, IA; Kim, JW; Lee, EB; Lee, EY; Song, YW	1
Chovanec, M; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Rajec, J	1
Beraldi, E; Crafter, C; Davies, BR; Fazli, L; Gleave, ME; Kim, S; Lamoureux, F; Thaper, D; Thomas, C; Zoubeidi, A	1
Delibas, N; Gocmen, AY; Gumuslu, S; Ocak, GA; Ozbilim, G	1
Atkinson, BJ; Bathala, T; Corn, P; Jonasch, E; Kalra, S; Tannir, NM; Wang, X	1
Boers-Sonderen, MJ; Hoentjen, F; Jacobs, JF; Mulder, SF; Nagtegaal, ID; van Herpen, CM; Wanten, GJ	1
Imai, H; Kageyama, S; Katayama, N; Matsuoka, N; Mizuno, T; Oda, H; Saito, K; Sugawara, Y; Tamaru, S; Uchida, K; Yamashita, Y	1
Choi, YJ; Jo, J; Kang, YK; Lee, JJ; Park, I; Park, JH; Ryoo, BY; Ryu, JS; Ryu, MH; Tan, E; Yoo, C	1
Cohen, PA; Finke, JH; Jaini, R; Rayman, P; Tuohy, VK	1
Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW	1
Demetri, GD; Jagannathan, J; Kang, YK; Kim, HJ; Lee, JJ; Nam, BH; Ramaiya, N; Ryoo, BY; Ryu, MH; Yoo, C	1
Li, T; Liu, J; Sai, X; Sun, Y; Wang, D; Yang, B; Zhou, R	1
Cui, Y; Ju, SH; Li, KC; Lu, T; Teng, GJ; Wen, S	1
Chakrabarti, A; Dhamija, P; Hota, D; Kochhar, R; Sachdev, A	1
Al-Hawary, M; Bylow, KA; Daignault, S; Dreicer, R; Grivas, PD; Hussain, M; Keller, ET; Kohli, M; Nanus, DM; Petrylak, DP; Smith, DC; Sottnik, JL; Stadler, WM; Tagawa, ST; Vaughn, DJ; Wong, SG	1
Cheng, X; Conney, AH; Cui, XX; Ding, N; Dipaola, RS; Du, Z; Goodin, S; Huang, MT; Liu, Y; Van Doren, J; Wang, H; Zheng, X	1
Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P	1
Armstrong, AJ; Chen, I; Chow-Maneval, E; Galsky, MD; Lechuga, M; Leopold, L; Michaelson, MD; Mooney, DJ; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Wang, SL; Wood, BA	1
Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R	1
Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL	1
Kasahara, M; Kuwabara, T; Mori, K; Mukoyama, M; Nakagawa, T; Ueshima, K; Yasuno, S; Yokoi, H	1
Camarillo, C; Jiang, L; Li, Y; Meng, J; Xu, C; Yao, Y; Zhang, Y	1
Balaña, C; Capellades, J; Gallego, O; Gil, MJ; Gonzalez, S; Perez, P; Reynes, G; Ribalta, T; Verger, E	1
Amato, AA; Puig, A; Scripko, PD	1
Coombes, JS; Fassett, RG; Geraghty, DP	1
Campese, VM	1
Berger, M; Ford, P; Goy, A; Hernandez-Ilzaliturri, FJ; Kahl, B; Protomastro, E	1
Fujisawa, M; Furukawa, J; Harada, K; Miyake, H; Nishikawa, M; Tei, H	1
Armstrong, ZB; Boughner, DR; Carruthers, CP; Drangova, M; Rogers, KA	1
Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S	1
Liang, X; Shi, Y	1
Bogaard, HJ; de Man, FS; de Raaf, MA; Gomez-Arroyo, J; Happé, C; Rol, N; Schalij, I; Voelkel, NF; Vonk-Noordegraaf, A; Westerhof, N	1
Büchert, M; Burkholder, I; Jaehde, U; Kanefendt, F; Kuhlmann, J; Moritz, B; Mross, K; Scheulen, M; Sörgel, F; Strumberg, D	1
Armstrong, AJ; Chen, I; Chow-Maneval, E; Clarke, SJ; Lechuga, M; Michaelson, MD; Paolini, J; Pond, GR; Smith, MR; Sonpavde, G; Templeton, AJ; Vardy, JL; Wang, SL	1
Gamou, T; Hayashi, K; Higashikata, T; Hirase, H; Ino, H; Kanaya, H; Katsuda, S; Kawashiri, MA; Konno, T; Michishita, I; Miwa, K; Mizuno, S; Nagase, K; Namura, M; Nitta, Y; Okeie, K; Sakata, K; Tada, H; Terashima, M; Uchiyama, K; Ueda, K; Yamagishi, M	1
Huang, XH; Hui, RT; Liu, G; Lu, J; Xu, YL; Zheng, XX	1
Bai, J; Cai, W; Feng, X; Han, Y; Liu, T; Tao, J; Tian, X; Yan, C; Zhang, X	1
Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A	1
Alonso, T; Díez, JJ; Grande, E; Iglesias, P	1
Arellano, ML; Berger, M; Borthakur, G; Luer, J; Raza, A	1
Choe, MS; Ha, JY; Jung, HR; Kim, BH; Kim, CI; Park, CH; Sohn, JC	1
Havekes, LM; Jukema, JW; Kühnast, S; Landmesser, U; Lüscher, TF; Pieterman, E; Princen, HM; Rensen, PC; Simic, B; van der Hoorn, JW; van der Tuin, SJ; van Klinken, JB; Willems van Dijk, K	1
Chngrian, GV; Mysyshin, MB; Semegen-Bodak, KV; Slaba, NA; Solomenchuk, TN	1
Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C	1
Casciano, R; Chua, A; Culver, K; Garrison, LP; Gorritz, M; Liu, Z; Pal, S; Perrin, A; Sherman, S; Wang, X	1
Buchfelder, M; Eyüpoglu, IY; Fan, Z; Ghoochani, A; Hatipoglu, G; Hock, SW; Savaskan, NE; Sehm, T; Weiss, R	1
Albiges, L; Escudier, B; Fizazi, K; Iacovelli, R; Loriot, Y; Massard, C; Massari, F	1
Borad, MJ; Bowles, DW; Calvo, E; Curtis, KK; Eckhardt, SG; Faessel, H; Gangolli, E; Goldman, J; Hidalgo, M; Parikh, A; Partyka, J; Rosen, LS; Ryan, DP; Stewart, S; Wirth, LJ	1
Chan, A; Chau, NM; Chue, XP; Ho, HK; Kanesvaran, R; Tan, MH; Teo, YL; Wee, HL	1
Adelaiye, R; Bard, J; Bjarnason, GA; Buck, M; Chintala, S; Ciamporcero, E; Conroy, D; Fetterly, G; Ku, SY; Miles, KM; Orillion, A; Pili, R; Prey, J; Ramakrishnan, S; Shen, L; Sotomayor, P; Tsompana, M	1
Aydin, S; Gizzi, M; Machiels, JP	1
Boratyn-Nowicka, A; Ćwikła, JB; Jarząb, B; Kos-Kudła, B; Michalik, B; Nawrocki, S; Piątek, M; Rogowski, W; Szabłowska-Siwik, S; Wachuła, E; Zemczak, A	1
Ito, T; Kutikov, A	1
Boglione, A; Comandone, A	1
Bianchi, L; Buonomo, O; Chimenti, MS; Chimenti, S; Chiricozzi, A; Faleri, S; Saraceno, R	1
Azad, A; Davis, ID; Espinoza, D; Goldstein, D; Harrison, M; Harvie, R; Hudson, AL; Jovanovic, L; Kannourakis, G; Kichenadasse, G; Long, A; Lowenthal, RM; Martin, A; Nelson, CC; Pavlakis, N; Shapiro, J; Steer, C; Stockler, MR; Thompson, JF; Yip, S	1
Baggstrom, M; Bogart, J; Crawford, J; Graziano, SL; Gu, L; Masters, GA; Miller, AA; Otterson, GA; Pang, HH; Ready, NE; Thomas, SP; Vokes, EE	1
Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Keizman, D; Kim, JJ; Leibowitz-Amit, R; Maimon, N; Mermershtain, W; Peer, A; Rouvinov, K; Sella, A; Sinibaldi, V; Weitzen, R	1
Albiges, L; Derosa, L; Escudier, B; Izzedine, H; Le Teuff, G	1
Chevreau, C; Culine, S; De Fromont, M; Escudier, B; Gravis, G; Jimenez, M; Laguerre, B; Ouali, M; Oudard, S; Ravaud, A; Rolland, F; Sevin, E; Theodore, C; Zanetta, S	1
Brewer, M; Cruz-Monserrate, Z; Houchen, CW; Janakiram, NB; Kumar, G; Lightfoot, S; Madka, V; May, R; Mohammed, A; Patlolla, JM; Rao, CV; Ritchie, RL; Sadeghi, M; Steele, VE; Yamada, HY	1
Chen, HM; Chen, SH; Coakley, BA; Divino, C; Eisenstein, S; Ferris, R; Gildener-Leapman, N; Kao, J; Ko, EC; Ma, G; Mandeli, J; Ozao, J; Pan, PY; Schwartz, M; Sung, M; Wang, LH	1
Boven, E; Castellano, D; Diekstra, MH; García-Donas, J; Gelderblom, H; Guchelaar, HJ; Mathijssen, RH; Rini, BI; Rodríguez-Antona, C; Swen, JJ	1
Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L	1
Burton, EA; Chartier, S; Habets, G; Jimenez-Andrade, JM; Lin, PS; Mantyh, PW; Thompson, ML; Tsai, J; West, BL	1
Demlova, R; Hezova, R; Kovarikova, A; Merhautova, J; Poprach, A; Radova, L; Slaby, O; Svoboda, M; Vyzula, R	1
Graepel, R; Lopes, F; McDougall, JJ; McKay, DM; Petri, B; Reyes, JL; Sharkey, KA; Wang, A	1
Badalamenti, G; Bronte, G; Casali, P; De Lisi, D; Dei Tos, AP; Frezza, AM; Fumagalli, E; Nannini, M; Pantaleo, MA; Russo, A; Santini, D; Spalato Ceruso, M; Tonini, G; Vincenzi, B	1
Li, CL; Shi, HZ; Tian, J	1
Bahl, A; Brown, J; Buchan, S; Hawkins, R; Jones, R; Pickering, L; Porfiri, E; Wagstaff, J	1
Grünwald, V; Ivanyi, P	1
Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D	1
Abdelraouf, F; Baas, P; Hasan, B; Menis, J; O'Brien, M; Popat, S; Smit, E; Surmont, VF; van Meerbeeck, JP	1
Banzato, A; Basso, U; Brunello, A; Diminutto, A; Fiduccia, P; Maruzzo, M; Roma, A; Zagonel, V; Zattoni, F; Zustovich, F	1
Bowes, MA; Bradley, JD; Conaghan, PG; Fuerst, T; Hrycaj, P; Irazoque-Palazuelos, F; Soma, K; Soto-Raices, O; van der Heijde, D; Wilkinson, B; Wu, C; Wyman, BT; Xie, Z; Zhang, R; Østergaard, M	1
Keck, B; Lieb, V; Lüdecke, G; Sikic, D	1
Barkhodari, A; Harshman, L; Minamimoto, R; Quon, A; Srinivas, S	1
Fang, L; Jiang, K; Wang, D; Wang, J; Zhao, J; Zhu, L	1
Boddy, AV; Galettis, P; Goulooze, SC; Martin, JH	1
Ait-Oudhia, S; Fetterly, G; Groman, A; Iyer, R; Mager, DE; Pokuri, V; Tomaszewski, G; Zagst, P	1
Chen, X; Li, CL; Shi, HZ; Tian, J; Wang, D	1
Bieche, I; Bousquet, G; Bryan, BA; de Gramont, A; Dos Santos, C; Faivre, S; Gapihan, G; Janin, A; Lopez, A; Martinet, M; Mitchell, DC; Neuzillet, C; Raymond, E; Riveiro, ME; Serova, M; Tijeras-Raballand, A	1
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Hornova, J; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M	1
Bryan, J; Griswold, M; Roda, M; Sirous, R; Smith, AD; Souza, F; Vasanji, A; Zhang, H; Zhang, X	1
Allman, K; Beach, J; Elson, P; Garcia, JA; Gilligan, T; Martin, A; Ornstein, MC; Rini, BI; Wood, L	1
Bananis, E; Connell, CA; Fleischmann, R; Hwang, LJ; Mease, PJ; Schwartzman, S; Soma, K; Takiya, L	1
Ha, HK; Kim, AY; Kim, HJ; Kim, JS; Lee, JS; Park, SH	1
Baker, H	1
Hossain, A; Mudano, AS; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA	1
Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C	1
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C	1
Adame, A; Fields, JA; Florio, J; He, JJ; Masliah, E; Metcalf, J; Overk, C; Rockenstein, E; Spencer, B; Wrasidlo, W	1
Chen, TW; Chen, YY; Chiang, KC; Liu, CT; Liu, YY; Tsai, CY; Wang, SY; Yeh, CN; Yeh, TS	1
Huang, S; Jonasch, E; Msaouel, P; Tannir, NM; Zurita, AJ	1
Guan, XY; Huang, XR; Lan, HY; Li, CJ; Lian, GY; Meng, XM; Tang, PM; Tang, YJ; To, KF; Wang, QM; Yan, BP; Zhou, S	1
Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA	1
Brener, SJ; Hu, T; Ivanc, TB	1
Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L	1
Adánez, G; Ayala, I; Castells, MT; García Pérez, B; Martín Castillo, A; Montes, A; Sánchez-Polo, MT	1
Kuczyk, MA; Merseburger, AS	1
Baum, CM; Bergsland, E; Fuchs, CS; Huang, X; Kulke, MH; Lenz, HJ; Li, JZ; Meropol, NJ; Picus, J; Posey, J; Ryan, DP; Stuart, K; Tye, L	1
Bybee, KA; Lavie, CJ; O'Keefe, JH	1
Cawley, PJ; Otto, CM	1
Alber, HF; Bartel, T; Dichtl, W; Feuchtner, GM; Grander, W; Hintringer, F; Müller, S; Pachinger, O; Reinthaler, M; Süssenbacher, A; Ulmer, H	1
Akgullu, C; Aydinlar, A; Kazazoglu, AR; Ozdemir, B; Yilmaz, Y	1
Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K	1
Antonescu, CR; Baum, CM; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; Griffith, D; Harlow, A; Heinrich, MC; Huang, X; Maki, RG; McKinley, A; Ou, WB; Town, A	1
Pedersen, TR	1
Brennan, DM; Nicholls, SJ; Nissen, SE; Tardif, JC; Tuzcu, EM	1
Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R	1
Brosa, M; Díaz, S; García del Muro, X; González, P; Grande, E; Paz-Ares, L	1
Beuselinck, B; Pans, S; Schöffski, P; Wolter, P	1
Cheng, S; Ge, S; Liu, D; Liu, X; Xu, G; Xu, J; Zhou, G	1
Andrieu, JM; Azizi, M; Banu, E; Chedid, A; Fournier, L; Helley, D; Medioni, J; Mejean, A; Oudard, S; Scotte, F	1
Chen, TY; Kuo, YL; Lin, WC; Tan, TY	1
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K	1
Soulières, D; Taussky, D	1
Calderan, L; Daducci, A; Degrassi, A; Farace, P; Galiè, M; Marzola, P; Merigo, F; Nicolato, E; Pesenti, E; Sbarbati, A	1
Gillessen, S; Omlin, A; Rothermundt, CA	1
Bergman, PJ; Boucher, JF; Couto, GC; Henry, CJ; Hintermeister, JG; Klein, MK; London, CA; Malpas, PB; Mauldin, GN; Michels, GM; Mitchener, KL; Rosenberg, MP; Rusk, AW; Wood-Follis, SL	1
Blay, JY; Reichardt, P	1
Bex, A; Boven, E; van der Veldt, AA	1
Kaburaki, J; Kuwana, M; Okazaki, Y	1
Kitas, GD; Melas, N; Saratzis, A; Saratzis, N	1
Choong, NW; Cohen, EE; Dekker, A; Hu, HS; Ivy, P; Karrison, TG; Kozloff, M; Taber, D; Vokes, EE; Wade, J	1
Reichardt, P	1
Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J	1
Blanke, CD	1
Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB	1
Altafullah, I; Birnbaum, G; Cree, B; Morra, VB; Orefice, G; Reder, A; Salvatore, E	1
Antonaci, S; Dituri, F; Fransvea, E; Giannelli, G; Lupo, L; Mazzocca, A	1
Dikilitas, M; Er, O; Karaca, H; Lale, A; Ozkan, M	1
Abe, F; Dafferner, A; Hoke, TA; Samson, H; Scholar, E; Talmadge, JE; Westphal, S; Younos, I	1
Calvo, A; Gil-Bazo, I; Gonzalez, A; Grande-Pulido, E; Guillén-Grima, F; Gurpide, A; Melero, I; Panizo, A; Perez-Gracia, JL; Prior, C; Segura, V	1
Abraham, C; Chalifour, LE; Dostanic, S; Mitmaker, B; Obrand, D; Schweitzer, M; Sheiner, N	1
Hohenberger, P	1
Goh, V; Juttla, J; Nathan, PD; Stott, D; Vinayan, A	1
Lieber, ML; Shah, SN; Smith, AD	1
Conney, AH; Cui, XX; Gao, Z; Huang, MT; Lin, Y; Liu, Y; Rabson, A; Reddy, B; Shih, WJ; Yang, CS; Zhao, Y; Zheng, X	1
Ardinghi, C; Bani, MR; Bernasconi, S; Carraro, F; Ghilardi, C; Giavazzi, R; Naldini, A; Oliva, P; Silini, A	1
Bex, A; Blank, C; Boven, E; Haanen, JB; Meijerink, MR; Van der Veldt, AA	1
Bergmann, L	1
Gschwend, JE	1
Marschner, N	1
Miller, K	1
Jäger, E	1
Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM	1
Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A	1
de Vries, JP; Hoefer, IE; Hurks, R; Kerver, M; Moll, FL; Pasterkamp, G; Schoneveld, A; Tangelder, MJ; Vink, A	1
Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD	1
Ferreira, GA; Sato, EI; Teixeira, AL	1
Casali, PG; Conca, E; Gronchi, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Pastorino, U; Pierotti, MA; Pilotti, S; Stacchiotti, S	1
Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K	1
Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD	1
Dykema, K; Ellis, L; Furge, K; Hammers, HJ; Jaspers, J; Netto, G; Paesante, S; Pili, R; Rudek, M; Salumbides, B; Shah, P; Sharma, R; Shen, L; Teh, BT; Verheul, HM	1
Arkadopoulos, N; Gennatas, C; Kondi-Pafiti, A; Michalaki, V	1
Ahlman, H; Andersson, A; Nilsson, B; Nilsson, E; Nilsson, O; Sjölund, K	1
Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O	1
Frank, PG; Lanza-Jacoby, S; Laury-Kleintop, L; Raval, M; Yan, G	1
Strandberg, TE	1
Bots, ML; Dogan, S; Duivenvoorden, R; Evans, GW; Grobbee, DE; Kastelein, JJ; Shear, CL; Visseren, FL	1
Figlin, RA; Huang, X; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Négrier, S; Patil, S	1
Biagi, JJ; Chalchal, HI; Eisenhauer, EA; Ellard, SL; Grimshaw, R; Hirte, H; Ivy, SP; Lee, U; Oza, AM; Sederias, J	1
Hiromatsu, Y; Matsuoka, K; Miyajima, J; Muraishi, K; Sasaki, Y; Sato, S; Suekane, S; Tajiri, Y; Tani, J; Tokubuchi, I; Yamada, K	1
del Muro, JG; Díaz, S; Grande, E; Paz-Ares, L	1
Chaskis, C; De Greve, J; Duerinck, J; Dujardin, M; Everaert, H; Lv, S; Michotte, A; Neyns, B; Nupponen, N; Sadones, J; Tynninen, O	1
Bauer, S; Grabellus, F; Schmid, KW; Sheu, SY; Speich, N; Worm, K	1
Ayllon, J; Barrascout, E; Beuselinck, B; Blesius, A; Elaidi, R; Escudier, B; Lang, H; Medioni, J; Morel, A; Oudard, S; Rixe, O; Schöffski, P; Wolter, P; Zucman-Rossi, J	1
Barni, S; Cabiddu, M; Carpo, M; Ghilardi, M; Petrelli, F	1
Bauerschlag, DO; Egberts, JH; Jonat, W; Kalthoff, H; Maass, N; Meinhold-Heerlein, I; Schem, C; Tiwari, S; Weigel, MT	1
Harward, ML; Jones, MA; Joyce, CJ; Kostner, KM; Kruger, PS; Roberts, MS; Venkatesh, B	1
Basappa, NS; Dreicer, R; Elson, P; Garcia, JA; Golshayan, AR; Rini, BI; Wood, L	1
Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA	1
Cho, JH; Kang, WK; Lee, J; Lim, HY; Park, JO; Park, S; Park, SH; Park, YS	1
Beck, M; Chang, HM; Cho, Y; Choi, DR; Kang, YK; Kim, TW; Lee, JL; Ryoo, BY; Ryu, MH; Yoon, DH	1
Benowitz, NL; Breazna, A; DeMicco, DA; Frey, P; Pipe, A; Samuels, L; Waters, DD; Wun, CC	1
Alacacioglu, A; Camci, C; Dikilitas, M; Er, O; Kalender, ME; Sagol, O; Sari, I; Sevinc, A; Soyuer, I; Yilmaz, U	1
Luo, H; Luo, M; Wang, J; Xiao, Y; Zhang, X	1
Ahmed, K; Ahn, Y; Cho, JG; Cho, SH; Choi, YH; Hachinohe, D; Hong, YJ; Hwang, SH; Jeong, MH; Kang, JC; Kim, JH; Kim, KH; Ko, JS; Lee, MG; Park, HW; Park, JC; Park, KH; Sim, DS; Yoon, HJ; Yoon, NS	1
Arnott, J; Bruce, JY; Carducci, M; Eickhoff, J; Liu, G; Logan, T; Pili, R; Treston, A; Wilding, G	1
Conley, A; George, S; Lazar, AJ; Nolden, L; Reynoso, D; Trent, JC; Wang, WL	1
Fenner, M; Ganser, A; Grünwald, V; Ivanyi, P; Länger, F; Merseburger, AS; Reuter, C; Seidel, C	1
Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A	1
Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P	1
Bang, YJ; Blanckmeister, C; Borbath, I; Chao, R; Chen, JS; Dahan, L; Hammel, P; Hörsch, D; Lombard-Bohas, C; Lu, DR; Metrakos, P; Patyna, S; Raoul, JL; Raymond, E; Ruszniewski, P; Smith, D; Valle, J; Van Cutsem, E; Vinik, A; Wiedenmann, B	1
Delle Fave, G; Jensen, RT	1
Bradshaw, MJ; Cheville, JC; Croghan, GA	1
Diebold, J; Hirschmann, A; Rössle, M	1
Ballantyne, C; Barter, P; Borgman, M; Chapman, MJ; Erbel, R; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS	1
Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T	1
Fujii, N; Inoue, H; Kameyama, T; Matsuki, A; Nozawa, T; Ohori, T; Shida, T; Sobajima, M; Suzuki, T	1
Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K	1
Bauer, S; Montemurro, M	1
Bouattour, M; Boucher, E; Cheng, AL; Dokmak, S; Douillard, JY; Dreyer, C; Faivre, S; Im, SA; Kang, YK; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E; Sablin, MP; Serrate, C; Vilgrain, V; Zappa, M	1
Ball, MJ; Cardinal, JW; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK	1
Abram, F; Choquette, D; Dorais, M; Haraoui, B; Martel-Pelletier, J; Pelletier, JP; Raynauld, JP; Wildi, LM	1
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z	1
Al-Batran, SE; Biesterfeld, S; Ebert, MP; Galle, PR; Hartmann, JT; Kabisch, M; Lordick, F; Moehler, M; Mueller, A; Reimer, P; Trarbach, T; Wachtlin, D; Weihrauch, M	1
Lee, J; Sharma, S; Steele, VE; Zhou, J	1
Nishida, T; Omori, T; Ueshima, S	1
Brufsky, AM; Copur, MS; Davis, J; Generali, D; Gernhardt, D; Giguere, JK; Gressot, L; Huang, X; Kern, KA; Liau, KF; Minton, SE; Paul, D; Richards, PD; Robert, NJ; Saleh, MN; Smith, JW	1
Chaitman, BR; Goldberger, JJ; Messig, M; Schwartz, GG	1
Beltran, L; Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Horenblas, S; Nathan, P; O'Brien, T; Peters, J; Powles, T; Sahdev, A; Sarwar, N; Shamash, J	1
Brown, A; Ginsberg, MS; James, L; Juergens, R; Kris, MG; Krug, LM; Markus, S; Paik, PK; Pietanza, MC; Rizvi, NA; Rudin, CM; Subzwari, S; Takebe, N; Travis, W; Tyson, L	1
Albain, KS; Besse, B; Blais, N; Chao, RC; Gervais, R; Hainsworth, JD; Hamm, JT; Kim, ST; Laskin, J; Lipton, A; Masters, GA; Natale, RB; Page, RD; Selaru, P	1
Chatellier, G; Cuenod, CA; Faraggi, M; Fournier, L; Hindié, E; Huchet, V; Hugonnet, F; Itti, E; Medioni, J; Oudard, S; Smadja, C	1
Hassanian, MA; Samy, W	1
Nemati, MH	1
Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM	1
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K	1
Birrer, MJ; Bowtell, D; Ellard, SL; Gilks, CB; Gout, PW; Huntsman, DG; Kagami, T; Lopez-Berestein, G; McAlpine, JN; Miller, DM; Mok, SC; Ozbun, L; Sood, AK; Stany, MP; Stone, RL; Vathipadiekal, V; Vivas-Mejia, P; Wang, Y; Wang, YZ; Xue, H	1
Boucher, E; Cheng, AL; DePrimo, SE; Douillard, JY; Faivre, S; Harmon, CS; Kim, JS; Lanzalone, S; Lechuga, MJ; Lim, HY; Lin, X; Raymond, E	1
Bex, A; Blank, C; Haanen, J; Horenblas, S; Meinhardt, W; van Tinteren, H	1
Filipiak, KJ; Langiewicz, P; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Zaborowska, M; Złnierek, J	1
Gao, H; Guo, W; Liu, X	1
Bergh, JJ; Mienie, LJ; Terre'Blanche, G; van der Walt, MM	1
Kiani, AN; Magder, LS; Petri, M; Post, WS	1
Enooku, K; Goto, T; Kanai, F; Koike, K; Kondo, Y; Masuzaki, R; Omata, M; Shiina, S; Tateishi, R; Yoshida, H	1
Elders, A; Fraser, C; Hislop, J; Jenkinson, D; Mowatt, G; Petty, R; Sharma, P; Vale, L	1
Carducci, MA; Eisenberger, MA; Hammers, H; Huang, P; Ish-Shalom, M; Keizman, D; Pili, R	1
Akkus, M; Baykara, M; Benekli, M; Buyukberber, S; Coskun, U; Dane, F; Dursun, A; Gonul, II; Sevinc, A; Yildiz, R	1
Ardoin, SP; Barnhart, HX; Bowyer, SL; Brunner, HI; Eberhard, A; Evans, GW; Higgins, GC; Ilowite, NT; Imundo, LF; Jung, L; Kimura, Y; Klein-Gitelman, M; McCurdy, D; Mieszkalski, KL; Provenzale, J; Punaro, M; Reed, AM; Sandborg, C; Schanberg, LE; Sherry, DD; Silver, R; Silverman, E; Singer, NG; Soep, JB; Thompson, SD; von Scheven, E; Wagner-Weiner, L; Wallace, C; Yow, E	1
Patel, S	1
Beer, C; Blacker, D; Bynevelt, M; Hankey, GJ; Puddey, IB	1
Amiri-Kordestani, L; Bates, SE; Fojo, T	1
Antoniades, C; Antonopoulos, AS; Bakogiannis, C; Brili, S; Hatzis, G; Papageorgiou, N; Stefanadis, C; Tousoulis, D	1
Aschermann, M; Downe, RW; Horak, J; Kovarnik, T; Kral, A; Linhart, A; Martasek, P; Mintz, GS; Mrazek, V; Skalicka, H; Skulec, R; Sonka, M; Uhrova, J; Wahle, A	1
Ballantyne, CM; Barter, PJ; Borgman, M; Chapman, MJ; Erbel, RM; Libby, P; Nicholls, SJ; Nissen, SE; Raichlen, JS; Uno, K; Wolski, K	1
Bouma, BJ; de Groot, E; Groenink, M; Luijendijk, P; Mulder, BJ; Pieper, PG; Sieswerda, GT; van Dijk, AP; Veen, G; Vliegen, HW; Vriend, JW; Zwinderman, AH	1
Luo, H; Luo, M; Wang, J; Xiao, Y	1
Feig, JE; Fernandez-Hernando, C; Fisher, EA; Garabedian, MJ; Rotllan, N; Shamir, R; Shang, Y; Torra, IP; Vengrenyuk, Y; Wu, C	1
Batteux, F; Chéreau, C; Kavian, N; Marut, W; Nicco, C; Servettaz, A; Weill, B	1
Janakiram, NB; Lightfoot, S; Mohammed, A; Qian, L; Rao, CV; Steele, VE	1
Einecke, D	1
Bruce, JN; Canoll, P; Christensen, JG; Crisman, C; D'Amico, R; Ebiana, V; Gil, O; Kennedy, BC; Lei, L; Rosenfeld, SS; Sisti, J	1
Burris, HA; Eakle, JF; Greco, FA; Hainsworth, JD; Lubiner, ET; Quinn, R; Rubin, MS; Shipley, D; Spigel, DR; Thompson, DS	1
Ballantyne, CM; Carlson, DM; Davidson, M; Maki, KC; Nicholls, SJ; Rosenson, RS; Setze, C; Stolzenbach, J	1
Heidenreich, A; van Essen, J	1
Bonenkamp, JJ; de Wilt, JH; Gelderblom, H; Hartgrink, HH; Sleijfer, S; Tielen, R; van Coevorden, F; van der Graaf, WT; Verhoef, C	1
Casali, PG; De Troia, B; Dei Tos, AP; Gronchi, A; Libertini, M; Marrari, A; Messina, A; Morosi, C; Negri, T; Palassini, E; Pilotti, S; Stacchiotti, S	1
Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R	1
Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP	1
Casciano, R; Chulikavit, M; Garrison, LP; Liu, Z; Perrin, A; Wang, X	1
Bai, W; He, AR; Hwang, J; Marshall, J; Mikhail, S; Navarro, R; Pishvaian, M; Shivapurkar, N; Wellstein, A	1
Byrne, MJ; Creaney, J; Dick, IM; Francis, RJ; Hasani, A; Millward, MJ; Musk, AW; Nowak, AK; Segal, A; van der Schaaf, A	1
Brown, K; Bucerius, J; Calcagno, C; Dickson, SD; Fayad, ZA; Fisher, EA; Fuster, V; Hayashi, K; Kotsuma, M; Lin, J; Moon, MJ; Moshier, E; Mounessa, JS; Nicolay, K; Ramachandran, S; Roytman, M; Rudd, JH; Tanimoto, T; Tsimikas, S; Vucic, E	1
Dreyer, C; Faivre, S; Raymond, E	1
Couvelard, A; de Gramont, A; Faivre, S; Hammel, P; Neuzillet, C; Raymond, E; Serova, M; Tijeras-Raballand, A	1
Babazono, T; Fujimoto, A; Imamoto, M; Kasahara, M; Kimura, G; Koya, D; Nakao, K; Sato, T; Tanaka, S; Ueshima, K; Yasuno, S	1
Agrillo, A; Facchini, A; Filiaci, F; Nastro Siniscalchi, E; Ungari, C	1
Aieta, M; Amadori, A; Barile, C; Basso, U; Borin, M; Celadin, R; Cristofanilli, M; Fassan, M; Grassi, A; Indraccolo, S; Jirillo, A; Lanza, C; Miatello, L; Rossi, E; Rugge, M; Sava, T; Troiani, L; Zamarchi, R; Zilio, F	1
Binongo, JN; Corban, MT; Dhawan, SS; Eshtehardi, P; Golub, L; Krishnan, SK; McDaniel, MC; Quyyumi, AA; Raggi, P; Samady, H	1
Kelly, WK; Lin, J	1
Ban, X; Cheng, W; Han, X; Hu, S; Jang, IK; Sun, Y; Tian, J; Yu, B; Yu, H; Zhang, S	1
Gong, P; Lin, J; Liu, S; Lu, J; Lu, X; Qiu, J; Wang, H; Zhang, X	1
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J	1
De Amici, M; Ganini, C; Giunta, V; Imarisio, I; Paglino, C; Porta, C; Quaglini, S; Sacchi, L	1
Barnett, AH; Cooke, MW; Gao, F; Hawkey, P; Hong, T; Jones, A; Linhartova, L; Melody, T; Patel, JM; Perkins, GD; Snaith, C; Thickett, DR	1
Benda, B; Bradley, JD; Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Krishnaswami, S; Nash, P; Song, YW; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Wyman, BT; Zerbini, C; Zwillich, SH	1
Adamova, IY; Afanasieva, OI; Atanesyan, RV; Ezhov, MV; Konovalov, GA; Matchin, YG; Pokrovsky, SN; Safarova, MS; Utkina, EA	1
Hayashi, M; Hayashida, R; Ishii, H; Jinno, Y; Murohara, T; Okada, K; Okumura, S; Sakakibara, M; Tanaka, A	1
Buti, S; Donini, M; Lazzarelli, S; Passalacqua, R	1
Shah, PK	1
Chu, E	1
Harman, SM; Hecht, HS	1
Bianchi, S; Bigazzi, R; Caiazza, A; Campese, VM	1
Nissen, SE	1
Chang, G; DeNofrio, D; Goldberg, L; Kao, A; Kolansky, DM; Loh, E; Pickering, F; Sasseen, B; See, VY; Wilensky, RL	1
Barrios, RJ; Greenberg, NM; Huss, WJ	1
Buckley, P; Doroshow, JH; Frankel, P; Galvin, I; Gandara, DR; Gosselin, R; Gumerlock, PH; Lara, PN; Lenz, HJ; Longmate, J; Mack, PC; Margolin, K; Meyers, FJ; Quinn, DI; Rao, J; Turrell, C; Valk, P; Wun, T	1
Brune, K	1
Kröger, K; Wittlinger, T	1
Brodie, B; Brown, BG; Cooper, CJ; Crowe, T; DeMaria, AN; Ganz, P; Grines, CL; Howard, G; Nissen, SE; Schoenhagen, P; Tuzcu, EM; Vogel, RA	1
Cressman, MD; Harris, S; Hutchinson, HG; Pears, JS; Vidt, DG	1
Akiba, T; Nihei, H; Nitta, K	1
Carlier, M; Claeys, MJ; Cools, F; Cosyns, B; De Meester, A; Dewit, B; Gobin, E; Hoffer, E; Missault, L; Vermeersch, P	1
Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW	1
Crowe, T; Ganz, P; Magorien, RD; Nissen, SE; O'Shaughnessy, C; Orazem, J; Sasiela, WJ; Schoenhagen, P; Tsai, J; Tuzcu, EM	1
Berlin, JD; Lockhart, AC; Lockhart, C	1
Ayaori, M; Fayad, ZA; Higashi, K; Iwamoto, N; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tamai, S; Taniguchi, H; Yonemura, A	1
Bhatt, DL; Karha, J	1
Cheng, X; Cheng, Y; Ge, H; Li, B; Liao, YH; Liu, Y; Lu, B; Wang, M; Yuan, J; Zhang, J	1
Bloomfield, P; Boon, NA; Cowell, SJ; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J	1
Rosenhek, R	1
Browne, P; Connor, DJ; Johnson-Traver, S; Launer, LJ; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, MN; Sparks, DL; Wassar, D; Ziolkowski, C	1
Baller, D; Burchert, W; Gleichmann, U; Horstkotte, D; Pulawski, E; Wielepp, P	1
Halmos, G; Kanashiro, CA; Nagy, A; Schally, AV; Stangelberger, A; Szepeshazi, K	1
Pai, RG	1
Adamovich, E; Butler, WM; Galbreath, RW; Kurko, B; Merrick, GS; Moyad, MA; Wallner, KE	1
Cairns, T; Cook, HT; Elliot, V	1
Chen, MS; Crowe, T; Kapadia, S; Loyd, AB; Nicholls, SJ; Nissen, SE; Schoenhagen, P; Sipahi, I; Tuzcu, EM	1
Boon, NA; Burton, J; Cowell, SJ; Houslay, ES; Newby, DE; Northridge, DB; Prescott, RJ; Reid, J	1
Berghaus, A; Dellian, M; Eichhorn, ME; Jonczyk, A; Strieth, S; Sutter, A	1
Cools, J; Debiec-Rychter, M; Folens, C; Marynen, P; Mentens, N; Prenen, H; Schöffski, P; Sciot, R; Van Oosterom, A	1
Boileau, C; Brunet, J; Laufer, S; Martel-Pelletier, J; Moreau, M; Pelletier, JP	1
Bertagnolli, MM; Demetri, GD; Desai, J; Fletcher, CD; George, S; Morgan, JA; Posner, M; Raut, CP; Zahrieh, D	1
Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC	1
Erbel, R; Schmermund, A	1
Obata, R; Takahashi, H; Tamaki, Y	1
Chen, YH; Chua, S; Hang, CL; Hung, WC; Wu, CJ; Yeh, KH; Yip, HK; Youssef, AA	1
Stadler, W	1
Abrams, ST; Farahani, M; Hughes, M; Jones, GM; Lakum, T; Lin, K; Slupsky, JR; Treweeke, AT; Zuzel, M	1
Healy, H; Morgan, C; Saltissi, D; Westhuyzen, J	1
Vollmer, H	1
Blay, JY; de Balincourt, C; di Paola, ED; Duffaud, F; Fowst, C; Hogendoorn, PC; Judson, I; Le Cesne, A; Leahy, M; Ray-Coquard, I; van Glabbeke, M; Verweij, J	1
Blanke, C	1
Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J	1
Buhaescu, I; Deray, G; Izzedine, H; Rixe, O	1
Bokemeyer, C; Bruweleit, M; Butzal, M; Draab, E; Fiedler, W; Fischer, U; Hossfeld, DK; Jücker, M; Loges, S; Metzner, A; O'-Farrel, AM; Schuch, G; Tinnefeld, H	1
Baum, CM; Bukowski, RM; Bycott, PW; Chen, I; Figlin, RA; Hutson, TE; Kim, ST; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rixe, O; Szczylik, C; Tomczak, P	1
Cuneo, KC; Fu, A; Geng, L; Osusky, KL	1
Hosoya, T; Kawamoto, S; Kawamura, T; Miyazaki, Y	1
Burns, N; Homma, N; Kraskauskas, D; McMurtry, IF; Morris, KG; Oka, M; Taraseviciene-Stewart, L; Voelkel, NF	1
Arisz, L; Kastelein, JJ; Koopman, MG; Ozsoy, RC; van der Steeg, WA	1
Bachinsky, WB; Duggan, WT; Lasala, GP; Nicholls, SJ; Nissen, SE; Revkin, JH; Ruzyllo, W; Shear, CL; Tardif, JC; Tuzcu, EM	1
Barter, PJ; Bots, ML; Burgess, L; Duggan, WT; Evans, GW; Grobbee, DE; Kastelein, JJ; Kuivenhoven, JA; Revkin, JH; Riley, WA; Shear, CL; van Leuven, SI	1
Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P	1
Canis, M; Hempel, JM; Mazurek, B; Olzowy, B; Suckfüll, M	1
Seynaeve, C; Sleijfer, S; Verweij, J; Wiemer, E	1
Archer, SL; Bonnet, S; Haromy, A; McMurtry, MS; Michelakis, ED	1
Demetri, G; Judson, I	1
Martel-Pelletier, J; Pelletier, JP	1
Azuma, A; Matsubara, H; Sasaki, S; Sawada, T; Yamada, T	1
Budoff, MJ; Gao, YL; Kessler, P; Mao, SS; Moustafa, M; Qunibi, W	1
Amann-Vesti, B; Brockes, C; Koppensteiner, R; Kovacevic, T; Rousson, V; Simon, R; Spring, S; van der Loo, B	1
Bui, B; Italiano, A	1
Atkins, JN; Belani, CP; Brahmer, JR; Chao, RC; Gillenwater, HH; Govindan, R; Novello, S; Pallares, C; Rosell, R; Sanchez, JM; Scagliotti, GV; Selaru, P; Socinski, MA; Tye, L	1
Ai, M; Asztalos, BF; Jones, PH; Nakajima, K; Otokozawa, S; Schaefer, EJ; Stein, E	1
Bradley, DA; Dreicer, R; Dunn, R; Hussain, M; Nanus, D; Rosenberg, J; Smith, DC; Stadler, W	1
Debiec-Rychter, M; Dziewirski, W; Grzesiakowska, U; Michej, W; Nowecki, Z; Ruka, W; Rutkowski, P; Siedlecki, JA; Szawłowski, A	1
Ferjan, M; Golicnik, A; Okrajsek, R; Radovancevic, B; Schlegel, TT; Starc, V; Vrtovec, B	1
Badimon, JJ; Chew, DP; Corti, R; Fallon, JT; Fayad, ZA; Fuster, V; Helft, G; Worthley, MI; Worthley, SG; Zaman, AG	1
Bybee, KA; Lee, JH; O'Keefe, JH	1
Asakura, M; Asanuma, H; Kato, H; Kim, J; Kitakaze, M; Liao, Y; Minamino, T; Ogai, A; Takashima, S; Zhao, H	1
Ball, MJ; Coombes, JS; Fassett, RG; Geraghty, DP; Robertson, IK	1
Aoki, M; Hadano, S; Ikeda, JE; Itoyama, Y; Kanno, T; Kohiki, E; Okada, Y; Onoe, K; Osuga, H; Otomo, A; Shouguchi-Miyata, J; Suga, E; Tanaka, K; Yanagisawa, Y	1
Budoff, M; Diaz-Buxo, JA; He, DY; Kessler, PD; Moustafa, M; Muenz, LR; Qunibi, W	1
Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ	1
Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG	1
Carter, SK	1
Brown, WV	1
Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK	1
Bakker Schut, TC; Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; Römer, TJ; van De Poll, SW; van Der Laarse, A; Volger, OL	1
Griffin, BP; Lauer, MS; Novaro, GM; Pearce, GL; Sprecher, DL; Tiong, IY	1
Giles, FJ	1

Reviews

45 review(s) available for pyrroles and Disease Exacerbation

Article	Year
Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis. PloS one, 2022, Volume: 17, Issue:3 Topics: Disease Progression; Glucocorticoids; Humans; Morpholines; Muscular Dystrophy, Duchenne; Piperidines; Prognosis; Pyrroles	2022
Plexiform Arteriopathy in Rodent Models of Pulmonary Arterial Hypertension. The American journal of pathology, 2019, Volume: 189, Issue:6 Topics: Animals; Disease Models, Animal; Disease Progression; Humans; Hypoxia; Indoles; MAP Kinase Signaling System; Mice; Mice, Knockout; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrroles; Rats	2019
Current understanding of the molecular biology of pancreatic neuroendocrine tumors. Journal of the National Cancer Institute, 2013, Jul-17, Volume: 105, Issue:14 Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Hypoxia; Co-Repressor Proteins; Cyclin-Dependent Kinase Inhibitor p18; Disease Progression; Disease-Free Survival; Everolimus; Gene Knock-In Techniques; Gene Knockout Techniques; Genetic Predisposition to Disease; Humans; Indoles; Islets of Langerhans; Molecular Chaperones; Molecular Targeted Therapy; Mutation; Neovascularization, Pathologic; Neuroendocrine Tumors; Nuclear Proteins; Octreotide; Pancreatic Neoplasms; Proto-Oncogene Proteins; Pyrroles; Receptor, Notch1; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2013
Do statins play a role in renoprotection? Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Adult; Aged; Albuminuria; Animals; Atorvastatin; Cardiovascular Diseases; Diet, High-Fat; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Metabolic Syndrome; Middle Aged; Pyrroles; Renal Insufficiency, Chronic	2014
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs. Clinical and experimental nephrology, 2014, Volume: 18, Issue:2 Topics: Acute Kidney Injury; Atorvastatin; Disease Progression; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rosuvastatin Calcium; Sulfonamides	2014
Effects of lipophilic statins for heart failure: a meta-analysis of 13 randomised controlled trials. Heart, lung & circulation, 2014, Volume: 23, Issue:10 Topics: Atorvastatin; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Stroke Volume; Ventricular Dysfunction, Left	2014
Kidney cancer in 2014: Key advances promise progress for kidney cancer patients. Nature reviews. Urology, 2015, Volume: 12, Issue:2 Topics: Angiogenesis Inhibitors; Carcinogenesis; Carcinoma, Renal Cell; Disease Progression; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Nephrons; Organ Sparing Treatments; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib	2015
Tofacitinib for the treatment of moderate-to-severe psoriasis. Expert review of clinical immunology, 2015, Volume: 11, Issue:4 Topics: Animals; Clinical Trials as Topic; Disease Progression; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; STAT Transcription Factors	2015
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?]. Aktuelle Urologie, 2015, Volume: 46, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis	2015
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism]. Der Urologe. Ausg. A, 2016, Volume: 55, Issue:5 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib	2016
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA). The Cochrane database of systematic reviews, 2016, 11-17, Volume: 11 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure	2016
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. The Cochrane database of systematic reviews, 2017, 03-10, Volume: 3 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure	2017
[Value of targeted therapies for renal cell cancer]. Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate	2008
Prevention of calcific aortic valve stenosis-fact or fiction? Annals of medicine, 2009, Volume: 41, Issue:2 Topics: Angiotensin-Converting Enzyme Inhibitors; Aortic Valve Stenosis; Atherosclerosis; Atorvastatin; Calcinosis; Cardiomyopathies; Disease Progression; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Renin-Angiotensin System	2009
Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. Expert review of anticancer therapy, 2009, Volume: 9, Issue:6 Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Europe; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Piperazines; Practice Guidelines as Topic; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib	2009
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence. Angiology, 2010, Volume: 61, Issue:2 Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin	2010
[Internal medical therapy of gastrointestinal stroma tumors]. Der Radiologe, 2009, Volume: 49, Issue:12 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Piperazines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib	2009
Recovery of paraneoplastic hypercalcemia by sunitinib treatment for renal cell carcinoma: a case report and review of the literature. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3 Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Humans; Hypercalcemia; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Paraneoplastic Syndromes; Pneumonectomy; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2010
[Aspects of surgical treatment for gastro-intestinal stromal tumors]. Der Radiologe, 2009, Volume: 49, Issue:12 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Diagnostic Imaging; Disease Progression; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Laparoscopy; Minimally Invasive Surgical Procedures; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sunitinib	2009
[Sunitinib--from paradigm shift to standard treatment of metastatic renal cell carcinoma]. Onkologie, 2010, Volume: 33 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Approval; Drug Delivery Systems; Drugs, Investigational; Evidence-Based Medicine; Germany; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sunitinib; Survival Rate	2010
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma]. Onkologie, 2010, Volume: 33 Suppl 1 Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate	2010
[First-line therapy of metastatic renal cell carcinoma--update 2009]. Onkologie, 2010, Volume: 33 Suppl 1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drugs, Investigational; Evidence-Based Medicine; Germany; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Prognosis; Pyrroles; Sirolimus; Sunitinib; Survival Rate	2010
Lipid-lowering drugs and heart failure: where do we go after the statin trials? Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Pravastatin; Primary Prevention; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Triglycerides	2010
Statins for multiple sclerosis. The Cochrane database of systematic reviews, 2010, Dec-08, Issue:12 Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention	2010
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer chemotherapy and pharmacology, 2011, Volume: 67 Suppl 1 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib	2011
The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. European urology, 2011, Volume: 60, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Patient Selection; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Survival Rate; Time Factors; Treatment Outcome	2011
Systematic review of escalated imatinib doses compared with sunitinib or best supportive care, for the treatment of people with unresectable/metastatic gastrointestinal stromal tumours whose disease has progressed on the standard imatinib dose. Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:2 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome	2012
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer treatment reviews, 2012, Volume: 38, Issue:5 Topics: Benzamides; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib	2012
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. Journal of the National Cancer Institute, 2011, Dec-07, Volume: 103, Issue:23 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Confounding Factors, Epidemiologic; Cross-Over Studies; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Interferon-gamma; Neoplasms; Patient Selection; Pyrroles; Randomized Controlled Trials as Topic; Research Design; Sunitinib; Treatment Outcome	2011
Statins for multiple sclerosis. The Cochrane database of systematic reviews, 2011, Dec-07, Issue:12 Topics: Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-beta; Multiple Sclerosis; Pyrroles; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin	2011
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Resistance, Neoplasm; Etoposide; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Medical Oncology; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2012
Targeting angiogenesis as a promising modality for the treatment of prostate cancer. The Urologic clinics of North America, 2012, Volume: 39, Issue:4 Topics: Angiogenesis Inhibitors; Anilides; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Male; Prostatic Neoplasms; Pyridines; Pyrroles; Signal Transduction; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A	2012
Pathobiology, not angiography, should guide management in acute coronary syndrome/non-ST-segment elevation myocardial infarction: the non-interventionist's perspective. Journal of the American College of Cardiology, 2003, Feb-19, Volume: 41, Issue:4 Suppl S Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Outcome Assessment, Health Care; Pyrroles; Randomized Controlled Trials as Topic	2003
Safety of anti-inflammatory treatment--new ways of thinking. Rheumatology (Oxford, England), 2004, Volume: 43 Suppl 1 Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; Gastrointestinal Diseases; Humans; Isoenzymes; Membrane Proteins; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrroles	2004
[Role of lipid lowering therapy in patients with peripheral arterial occlusive disease]. Herz, 2004, Volume: 29, Issue:1 Topics: Anticholesteremic Agents; Arterial Occlusive Diseases; Atorvastatin; Disease Progression; Exercise Test; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Jejunoileal Bypass; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome	2004
Rosuvastatin-induced arrest in progression of renal disease. Cardiology, 2004, Volume: 102, Issue:1 Topics: Aged; Atorvastatin; Controlled Clinical Trials as Topic; Creatine; Disease Progression; Drug Administration Schedule; Female; Fluorobenzenes; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney; Kidney Diseases; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2004
The epidermal growth factor receptor as a target for colorectal cancer therapy. Seminars in oncology, 2005, Volume: 32, Issue:1 Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction	2005
Statins and aortic stenosis progression: are biologic targets still an option? Current cardiology reports, 2005, Volume: 7, Issue:6 Topics: Aortic Valve Stenosis; Atorvastatin; Disease Progression; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles	2005
Advances in the treatment of gastrointestinal stromal tumours. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 10 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib	2007
DMOAD developments: present and future. Bulletin of the NYU hospital for joint diseases, 2007, Volume: 65, Issue:3 Topics: Acetates; Anthraquinones; Antirheumatic Agents; Chondroitin; Clinical Trials as Topic; Diphosphonates; Disease Progression; Doxycycline; Glucosamine; Humans; Hyaluronic Acid; Matrix Metalloproteinase Inhibitors; Osteoarthritis; Pyrroles; Risk Factors	2007
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications]. Bulletin du cancer, 2008, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles	2008
Cumulative clinical trial data on atorvastatin for reducing cardiovascular events: the clinical impact of atorvastatin. Current medical research and opinion, 2008, Volume: 24, Issue:4 Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus; Disease Progression; Heptanoic Acids; Humans; Kidney Failure, Chronic; Pyrroles; Risk Factors; Stroke	2008
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. Kidney international. Supplement, 1999, Volume: 71 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta	1999
Cholesterol lowering in atherosclerosis. The American journal of cardiology, 2000, Aug-24, Volume: 86, Issue:4B Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Simvastatin	2000
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. The oncologist, 2001, Volume: 6 Suppl 5 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Disease Progression; Endothelial Growth Factors; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Indoles; Lymphokines; Matrix Metalloproteinases; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2001

Trials

120 trial(s) available for pyrroles and Disease Exacerbation

Article	Year
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis. Arthritis research & therapy, 2019, 10-21, Volume: 21, Issue:1 Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2019
Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine, 2020, Volume: 55 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Everolimus; Female; Humans; Hypercholesterolemia; Hyperglycemia; Indoles; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Protein Kinase Inhibitors; Proteinuria; Pyrroles; Pyrrolidines; Survival Analysis	2020
Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 01-20, Volume: 39, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Time Factors; United Kingdom	2021
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 10-01, Volume: 39, Issue:28 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Disease Progression; Drug Administration Schedule; Europe; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Mutation; North America; Phenylurea Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazoles; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Time Factors; Triazines	2021
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies. The Journal of rheumatology, 2018, Volume: 45, Issue:2 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome	2018
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6. Arthritis care & research, 2019, Volume: 71, Issue:1 Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Probability; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome	2019
Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients. Rheumatology (Oxford, England), 2018, 08-01, Volume: 57, Issue:8 Topics: Adult; Disease Progression; Double-Blind Method; Female; Humans; Janus Kinase 3; Magnetic Resonance Imaging; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Spondylitis, Ankylosing; Thoracic Vertebrae; Treatment Outcome	2018
Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer. Investigational new drugs, 2019, Volume: 37, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepines; Bevacizumab; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Salvage Therapy; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2019
Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. The Journal of rheumatology, 2019, Volume: 46, Issue:9 Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Psoriatic; C-Reactive Protein; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome	2019
A phase II study of sunitinib in advanced hepatocellular carcinoma. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2013, Volume: 45, Issue:8 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pyrroles; Risk Assessment; Risk Factors; Sunitinib; Survival Analysis; Treatment Outcome	2013
Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Annals of the rheumatic diseases, 2014, Volume: 73, Issue:3 Topics: Adolescent; Age Factors; Atherosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Male; Prospective Studies; Puberty; Pyrroles; Treatment Outcome	2014
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid	2013
Atorvastatin therapy is not associated with slowing the progression of aortic stenosis: findings of a randomized controlled trial. Clinical laboratory, 2013, Volume: 59, Issue:3-4 Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Disease Progression; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles	2013
Tofacitinib prevents radiographic progression in rheumatoid arthritis. Journal of Korean medical science, 2013, Volume: 28, Issue:8 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiography; Severity of Illness Index; Treatment Outcome	2013
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib. British journal of cancer, 2013, Oct-29, Volume: 109, Issue:9 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Benzimidazoles; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolones; Sunitinib	2013
Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology, 2013, Volume: 14, Issue:12 Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Republic of Korea; Sunitinib; Time Factors; Treatment Outcome	2013
Randomized clinical trial: atorvastatin versus placebo in patients with acute exacerbation of mild to moderate ulcerative colitis. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2014, Volume: 33, Issue:2 Topics: Acute Disease; Adult; Atorvastatin; Colitis, Ulcerative; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intention to Treat Analysis; Male; Middle Aged; Placebo Effect; Prednisolone; Pyrroles; Severity of Illness Index	2014
Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer, 2014, Mar-01, Volume: 120, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Transitional Cell; Confounding Factors, Epidemiologic; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrroles; Sample Size; Sunitinib; Treatment Outcome; Urologic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2014
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, 03-10, Volume: 32, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult	2014
Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU international, 2014, Volume: 114, Issue:6b Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Discovery; Gossypol; Humans; Indoles; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Radiography; Retrospective Studies; Sunitinib; Survival Rate; Taxoids; Time Factors	2014
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jan-10, Volume: 32, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome	2014
Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study. Targeted oncology, 2014, Volume: 9, Issue:4 Topics: Aged; Antineoplastic Agents; Biopsy; Brain Neoplasms; Disease Progression; Disease-Free Survival; Female; Glioblastoma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Radiotherapy; Sunitinib; Time Factors; Treatment Outcome	2014
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrroles; Treatment Outcome	2014
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate	2014
FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. International journal of clinical pharmacology and therapeutics, 2014, Volume: 52, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Colorectal Neoplasms; Disease Progression; Fluorouracil; Humans; Indoles; Leucovorin; Liver Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3	2014
Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clinical genitourinary cancer, 2014, Volume: 12, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Hemoglobins; Humans; Indoles; Inflammation; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Placebos; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Pyrroles; Retrospective Studies; Sunitinib; Taxoids	2014
Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study. Heart and vessels, 2015, Volume: 30, Issue:5 Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Coronary Angiography; Coronary Artery Disease; Disease Progression; Drug Combinations; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Plaque, Atherosclerotic; Prospective Studies; Pyrroles; Time Factors; Treatment Outcome; Ultrasonography, Interventional	2015
A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clinical lymphoma, myeloma & leukemia, 2014, Volume: 14, Issue:6 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Thrombocytopenia; Treatment Outcome	2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Mar-01, Volume: 21, Issue:5 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gene Expression; Hedgehog Proteins; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms; Pyridines; Pyrroles; Retreatment; RNA, Messenger; Signal Transduction; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1	2015
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Australia; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Everolimus; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome	2015
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-20, Volume: 33, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Humans; Indoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome	2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Sunitinib; Time Factors; Treatment Outcome	2015
Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Sep-15, Volume: 21, Issue:18 Topics: Antineoplastic Agents; CD11b Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cell Survival; Disease Progression; Flow Cytometry; Humans; Immune System; Immunosuppressive Agents; Indoles; Leukocytes, Mononuclear; Monocytes; Myeloid Cells; Neoplasm Metastasis; Neoplasms; Phosphorylation; Pyrroles; Radiosurgery; Sialic Acid Binding Ig-like Lectin 3; STAT3 Transcription Factor; Sunitinib; Treatment Outcome	2015
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leukemia & lymphoma, 2015, Volume: 56, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine	2015
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061). European journal of cancer (Oxford, England : 1990), 2016, Volume: 54 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Patient Selection; Positron-Emission Tomography; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Sample Size; Small Cell Lung Carcinoma; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2016
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati Annals of the rheumatic diseases, 2016, Volume: 75, Issue:6 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Marrow; Bone Marrow Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Synovitis; Treatment Outcome; Wrist Joint	2016
Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker. CPT: pharmacometrics & systems pharmacology, 2016, Volume: 5, Issue:6 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Humans; Indoles; Liver Neoplasms; Models, Theoretical; Neovascularization, Pathologic; Pilot Projects; Pyrroles; Sunitinib; Survival Rate; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2016
Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy. Radiology, 2016, Volume: 281, Issue:2 Topics: Aged; Aged, 80 and over; Algorithms; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Middle Aged; Prospective Studies; Pyrroles; Quality of Life; Response Evaluation Criteria in Solid Tumors; Software; Sunitinib; Surveys and Questionnaires; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Vascular Neoplasms	2016
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group. Clinical rheumatology, 2017, Volume: 36, Issue:1 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Regression Analysis; Surveys and Questionnaires; Treatment Outcome	2017
Activity of sunitinib in patients with advanced neuroendocrine tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-10, Volume: 26, Issue:20 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoid Tumor; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality of Life; Risk Assessment; Single-Blind Method; Sunitinib; Survival Analysis; Treatment Outcome	2008
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). The American journal of cardiology, 2008, Sep-15, Volume: 102, Issue:6 Topics: Aged; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; C-Reactive Protein; Calcinosis; Cholesterol; Disease Progression; Female; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Tomography, X-Ray Computed	2008
Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease. Acta cardiologica, 2008, Volume: 63, Issue:4 Topics: Atorvastatin; Coronary Artery Disease; Coronary Vessels; Disease Progression; Elasticity; Female; Health Status Indicators; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Pyrroles; Risk Factors; Vascular Resistance	2008
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Nov-20, Volume: 26, Issue:33 Topics: Adult; Aged; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib	2008
Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosi Circulation, 2008, Dec-09, Volume: 118, Issue:24 Topics: Aged; Atorvastatin; Cholesterol Ester Transfer Proteins; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Potassium; Pyrroles; Quinolines; Sodium; Ultrasonography	2008
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib	2009
Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:12 Topics: Algorithms; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Health Resources; Humans; Imatinib Mesylate; Indoles; Markov Chains; Models, Econometric; Neoplasm Metastasis; Piperazines; Placebos; Pyrimidines; Pyrroles; Sunitinib; Survival Analysis; Treatment Failure	2008
Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Investigational new drugs, 2010, Volume: 28, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Demography; Disease Progression; Female; Head and Neck Neoplasms; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Survival Analysis; Tomography, X-Ray Computed	2010
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung cancer (Amsterdam, Netherlands), 2010, Volume: 70, Issue:2 Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib	2010
Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. Lupus, 2010, Volume: 19, Issue:8 Topics: Adult; Atorvastatin; Chemokine CXCL9; Chemokines; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferons; Lupus Erythematosus, Systemic; Pyrroles; Severity of Illness Index	2010
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Molecular cancer therapeutics, 2010, Volume: 9, Issue:5 Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulins, Intravenous; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sunitinib; Tomography, X-Ray Computed; Tumor Cells, Cultured	2010
Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Annals of medicine, 2010, Volume: 42, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Carotid Artery, Internal; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reproducibility of Results; Tunica Intima; Ultrasonography	2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrroles; Recurrence; Sunitinib; Survival Analysis	2011
Phase II study of sunitinib malate in patients with recurrent high-grade glioma. Journal of neuro-oncology, 2011, Volume: 103, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Central Nervous System Neoplasms; Cerebrovascular Circulation; Disease Progression; Female; Glioma; Humans; Indoles; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrroles; Pyrrolidinones; Receptors, Platelet-Derived Growth Factor; Recurrence; Regional Blood Flow; Sunitinib; Vascular Endothelial Growth Factor Receptor-2	2011
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. American journal of respiratory and critical care medicine, 2011, Mar-15, Volume: 183, Issue:6 Topics: Aged; Aged, 80 and over; Atorvastatin; C-Reactive Protein; Cholesterol; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Hospital Mortality; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Interleukin-6; Male; Middle Aged; Prospective Studies; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome	2011
Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials). The American journal of cardiology, 2011, Jan-15, Volume: 107, Issue:2 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Heart Rate; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Simvastatin; Smoking; Survival Rate; Treatment Outcome; United States	2011
Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis. Circulation journal : official journal of the Japanese Circulation Society, 2011, Volume: 75, Issue:2 Topics: Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Korea; Male; Plaque, Atherosclerotic; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional	2011
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: 2-Methoxyestradiol; Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Colloids; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Estradiol; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nanoparticles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sunitinib; Survival Analysis; Treatment Failure; United States	2012
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. The New England journal of medicine, 2011, Feb-10, Volume: 364, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sunitinib	2011
Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN). Current medical research and opinion, 2011, Volume: 27, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography	2011
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Perfusion Imaging; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2011
Effects of atorvastatin on NGAL and cystatin C in chronic kidney disease: a post hoc analysis of the LORD trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:1 Topics: Acute-Phase Proteins; Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cystatin C; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Lipocalin-2; Lipocalins; Male; Middle Aged; Prognosis; Proto-Oncogene Proteins; Pyrroles; Young Adult	2012
Risk factors predictive of joint replacement in a 2-year multicentre clinical trial in knee osteoarthritis using MRI: results from over 6 years of observation. Annals of the rheumatic diseases, 2011, Volume: 70, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Knee; C-Reactive Protein; Disease Progression; Epidemiologic Methods; Female; Humans; Knee Joint; Magnetic Resonance Imaging; Male; Menisci, Tibial; Middle Aged; Naproxen; Osteoarthritis, Knee; Prognosis; Pyrroles; Tibial Meniscus Injuries	2011
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Mutation; Prospective Studies; Protein-Tyrosine Kinases; Pyrroles; Stomach Neoplasms; Sunitinib; Treatment Outcome	2011
Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clinical breast cancer, 2011, Volume: 11, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis	2011
High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. American heart journal, 2011, Volume: 161, Issue:5 Topics: Atorvastatin; Atrial Fibrillation; Cholesterol; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Electrocardiography; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Ischemic Attack, Transient; Male; Middle Aged; Pyrroles; Retrospective Studies; Stroke; Survival Rate; Time Factors; Treatment Outcome	2011
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Recurrence; Thrombocytopenia; Topotecan	2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 74, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pyrroles; Sunitinib; Survival Analysis	2011
Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cell Hypoxia; Cohort Studies; Disease Progression; Humans; Indoles; Kidney Neoplasms; Middle Aged; Misonidazole; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Young Adult	2011
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2011, Volume: 12, Issue:2 Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides	2011
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib. Journal of translational medicine, 2011, Jul-25, Volume: 9 Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Neoplasm Proteins; Pyrroles; ROC Curve; Sunitinib; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor C	2011
A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ. Urology, 2011, Volume: 78, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Probability; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome	2011
Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Rheumatology (Oxford, England), 2011, Volume: 50, Issue:11 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium; Carotid Artery Diseases; Carotid Intima-Media Thickness; Comorbidity; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Lupus Erythematosus, Systemic; Male; Maryland; Pyrroles	2011
Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times. Journal of gastroenterology, 2012, Volume: 47, Issue:1 Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Oxindoles; Propionates; Protein Kinase Inhibitors; Protein Precursors; Prothrombin; Pyrroles; Time Factors; Treatment Outcome; Tumor Burden	2012
Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis and rheumatism, 2012, Volume: 64, Issue:1 Topics: Adolescent; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Intima-Media Thickness; Child; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Lipids; Lupus Erythematosus, Systemic; Male; Pyrroles; Treatment Outcome; Young Adult	2012
A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan. International journal of stroke : official journal of the International Stroke Society, 2012, Volume: 7, Issue:2 Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Biphenyl Compounds; Brain Ischemia; Cerebral Infarction; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Irbesartan; Male; Middle Aged; Monitoring, Physiologic; Pyrroles; Sample Size; Stroke; Tetrazoles; Tomography, X-Ray Computed; Treatment Outcome	2012
Effects of atorvastatin on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young subjects with successfully repaired coarctation of aorta. Heart (British Cardiac Society), 2012, Volume: 98, Issue:4 Topics: Adult; Aortic Coarctation; Atorvastatin; Biomarkers; Cell Adhesion Molecules; Cytokines; Disease Progression; Endothelium, Vascular; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Period; Prognosis; Prospective Studies; Pyrroles; Time Factors; Vascular Surgical Procedures	2012
Virtual histology evaluation of atherosclerosis regression during atorvastatin and ezetimibe administration: HEAVEN study. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:1 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Cell Adhesion Molecules; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins; Male; Middle Aged; Plaque, Atherosclerotic; Pyrroles; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional	2012
Effect of two intensive statin regimens on progression of coronary disease. The New England journal of medicine, 2011, Dec-01, Volume: 365, Issue:22 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional	2011
Rationale and design of a trial on the effect of high dose statins on cardiovascular risk in adults after successful coarctation repair. Contemporary clinical trials, 2012, Volume: 33, Issue:2 Topics: Adult; Aortic Coarctation; Atherosclerosis; Atorvastatin; Cardiac Surgical Procedures; Carotid Arteries; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; History, Ancient; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Postoperative Care; Prospective Studies; Pyrroles; Treatment Outcome; Ultrasonography	2012
Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Disease Progression; Female; Humans; Indoles; Induction Chemotherapy; Irinotecan; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pyrroles; Small Cell Lung Carcinoma; Sunitinib; Treatment Outcome	2012
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovascular drugs and therapy, 2012, Volume: 26, Issue:4 Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Risk Factors; Triglycerides	2012
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Disease Progression; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Indoles; Male; Middle Aged; Mitotane; Pyrroles; Sunitinib; Treatment Outcome; Young Adult	2012
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:9 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Prospective Studies; Pyrroles; Sunitinib; Survival Rate	2012
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial. Clinical and experimental nephrology, 2013, Volume: 17, Issue:2 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Data Interpretation, Statistical; Disease Progression; Dyslipidemias; Endpoint Determination; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Function Tests; Male; Middle Aged; Prospective Studies; Pyrroles; Renal Insufficiency, Chronic; Research Design; Treatment Outcome	2013
Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function. The Journal of invasive cardiology, 2012, Volume: 24, Issue:10 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Artery Disease; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Microvessels; Middle Aged; Phenotype; Pilot Projects; Pyrroles; Regional Blood Flow; Retrospective Studies; Treatment Outcome; Ultrasonography, Interventional; Vascular Resistance	2012
Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions. Journal of cardiovascular pharmacology and therapeutics, 2013, Volume: 18, Issue:2 Topics: Aged; Angina, Unstable; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Pyrroles	2013
Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial). Critical care (London, England), 2012, Dec-11, Volume: 16, Issue:6 Topics: Anti-Inflammatory Agents; Atorvastatin; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Length of Stay; Male; Middle Aged; Patient Readmission; Pyrroles; Sepsis; Severity of Illness Index; Treatment Outcome	2012
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis and rheumatism, 2013, Volume: 65, Issue:3 Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Resistance; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Motor Activity; Piperidines; Pyrimidines; Pyrroles; Radiography; Treatment Outcome	2013
Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis. Supplements, 2013, Volume: 14, Issue:1 Topics: Adult; Atorvastatin; Biomarkers; Blood Component Removal; Chi-Square Distribution; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles; Russia; Time Factors; Treatment Outcome	2013
A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003, Volume: 41, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Chronic Disease; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Kidney Diseases; Kidney Glomerulus; Male; Middle Aged; Prospective Studies; Proteinuria; Pyrroles	2003
Effect of atorvastatin on postcardiac transplant increase in low-density lipoprotein cholesterol reduces development of intimal hyperplasia and progression of endothelial dysfunction. The American journal of cardiology, 2003, Jul-01, Volume: 92, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Endothelium, Vascular; Female; Heart Transplantation; Heptanoic Acids; Humans; Hyperplasia; Immunosuppressive Agents; Male; Middle Aged; Mycophenolic Acid; Postoperative Period; Pyrroles; Tunica Intima	2003
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-15, Volume: 9, Issue:13 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pyrroles; Recombinant Proteins; Time Factors; Tomography, Emission-Computed; Treatment Outcome; Vascular Endothelial Growth Factor A	2003
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004, Mar-03, Volume: 291, Issue:9 Topics: Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Function Tests; Male; Middle Aged; Observer Variation; Pravastatin; Pyrroles; Ultrasonography, Interventional	2004
Short-term effect of atorvastatin on ischaemic threshold in hypercholesterolaemic patients with stable ischaemic heart disease. Acta cardiologica, 2004, Volume: 59, Issue:3 Topics: Aged; Angina Pectoris; Atorvastatin; Cholesterol, LDL; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Ischemia; Pyrroles; Time Factors	2004
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging. Magnetic resonance imaging, 2004, Volume: 22, Issue:9 Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin	2004
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. The New England journal of medicine, 2005, Jan-06, Volume: 352, Issue:1 Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Artery Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Regression Analysis; Risk Factors; Secondary Prevention; Ultrasonography, Interventional	2005
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. Journal of the American College of Cardiology, 2005, Mar-01, Volume: 45, Issue:5 Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Treatment Outcome	2005
A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. The New England journal of medicine, 2005, Jun-09, Volume: 352, Issue:23 Topics: Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Atorvastatin; Blood Flow Velocity; Calcinosis; Cholesterol, LDL; Disease Progression; Double-Blind Method; Echocardiography, Doppler; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Treatment Failure	2005
Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. Current Alzheimer research, 2005, Volume: 2, Issue:3 Topics: Activities of Daily Living; Aged; Alzheimer Disease; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cognition; Depression; Disease Progression; Double-Blind Method; Female; Free Radicals; Heptanoic Acids; Humans; Male; Mental Status Schedule; Pilot Projects; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome	2005
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease. European journal of nuclear medicine and molecular imaging, 2005, Volume: 32, Issue:12 Topics: Aged; Atorvastatin; Blood Flow Velocity; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Disease Progression; Exercise Test; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Radionuclide Imaging; Treatment Outcome; Vasodilation; Ventricular Dysfunction, Left	2005
Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. Atherosclerosis, 2006, Volume: 189, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrroles; Severity of Illness Index; Treatment Outcome; Ultrasonography, Interventional	2006
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart (British Cardiac Society), 2006, Volume: 92, Issue:9 Topics: Adult; Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Tomography, Spiral Computed; Treatment Failure	2006
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). The American journal of cardiology, 2006, Jun-01, Volume: 97, Issue:11 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors	2006
Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clinical and experimental nephrology, 2006, Volume: 10, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Pyrroles; Renal Dialysis; Triglycerides	2006
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Gastrointestinal Stromal Tumors; Guanidines; Humans; Infusions, Intravenous; Male; Middle Aged; Pyrroles; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Treatment Outcome	2007
Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leukemia & lymphoma, 2006, Volume: 47, Issue:12 Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Separation; Disease Progression; DNA Primers; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Indoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; STAT5 Transcription Factor; Treatment Outcome; Vascular Endothelial Growth Factor A	2006
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England journal of medicine, 2007, Jan-11, Volume: 356, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sunitinib	2007
Effect of torcetrapib on the progression of coronary atherosclerosis. The New England journal of medicine, 2007, Mar-29, Volume: 356, Issue:13 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines; Ultrasonography, Interventional	2007
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. The New England journal of medicine, 2007, Apr-19, Volume: 356, Issue:16 Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Prospective Studies; Pyrroles; Quinolines	2007
Effect of atorvastatin on progression of sensorineural hearing loss and tinnitus in the elderly: results of a prospective, randomized, double-blind clinical trial. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2007, Volume: 28, Issue:4 Topics: Aged; Atorvastatin; Audiometry; Auditory Threshold; Cholesterol; Cholesterol, LDL; Disease Progression; Double-Blind Method; Female; Hearing Loss, Sensorineural; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Presbycusis; Prospective Studies; Pyrroles; Speech Perception; Tinnitus; Treatment Outcome	2007
Randomized evaluation of atorvastatin in patients with coronary heart disease: a serial intravascular ultrasound study. Circulation journal : official journal of the Japanese Circulation Society, 2007, Volume: 71, Issue:12 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Disease Progression; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Ultrasonography, Interventional	2007
The interscan variation of CT coronary artery calcification score: analysis of the Calcium Acetate Renagel Comparison (CARE)-2 study. Academic radiology, 2008, Volume: 15, Issue:1 Topics: Acetates; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Reproducibility of Results; Sevelamer; Tomography, X-Ray Computed; Treatment Outcome	2008
High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thrombosis and haemostasis, 2008, Volume: 99, Issue:1 Topics: Aged; Ankle; Atorvastatin; Blood Pressure; Brachial Artery; Cardiovascular Diseases; Carotid Arteries; Disease Progression; Endothelium, Vascular; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Peripheral Vascular Diseases; Pilot Projects; Prospective Studies; Pyrroles; Research Design; Time Factors; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography; Vasodilation	2008
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cause of Death; Cisplatin; Disease Progression; Drug Administration Schedule; Fatigue; Female; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pain; Protein-Tyrosine Kinases; Pyrroles; Remission Induction; Stomatitis; Sunitinib; Treatment Outcome	2008
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. The American journal of cardiology, 2008, Feb-01, Volume: 101, Issue:3 Topics: Aged; Atorvastatin; Cell Count; Cholesterol, LDL; Disease Progression; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides	2008
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design. Clinical genitourinary cancer, 2007, Volume: 5, Issue:7 Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Endpoint Determination; Humans; Indoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Research Design; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A	2007
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. Journal of cardiac failure, 2008, Volume: 14, Issue:2 Topics: Atorvastatin; Death, Sudden, Cardiac; Disease Progression; Female; Health Status Indicators; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyrroles; Risk Factors; Stroke Volume	2008
The Lipid lowering and Onset of Renal Disease (LORD) Trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC nephrology, 2008, Mar-18, Volume: 9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Probability; Pyrroles; Reference Values; Severity of Illness Index; Treatment Outcome	2008
A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2008, Volume: 51, Issue:6 Topics: Acetates; Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium Compounds; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Heptanoic Acids; Humans; Male; Middle Aged; Polyamines; Prospective Studies; Pyrroles; Renal Dialysis; Sevelamer; Time Factors	2008
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. American heart journal, 2001, Volume: 141, Issue:5 Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed	2001

Other Studies

228 other study(ies) available for pyrroles and Disease Exacerbation

Article	Year
Systemic study of selected histone deacetylase inhibitors in cardiac complications associated with cancer cachexia. Canadian journal of physiology and pharmacology, 2022, Volume: 100, Issue:3 Topics: Animals; Benzamides; Butyric Acid; Cachexia; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Heart Diseases; Histone Deacetylase Inhibitors; Hydroxamic Acids; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Pyridines; Pyrroles	2022
Capivasertib delays disease progression. Nature reviews. Clinical oncology, 2023, Volume: 20, Issue:9 Topics: Disease Progression; Humans; Pyrimidines; Pyrroles	2023
Tofacitinib for the Treatment of Refractory Polymyositis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2019, Volume: 25, Issue:8 Topics: Antirheumatic Agents; Biopsy; Disease Progression; Drug Resistance, Multiple; Electromyography; Female; Humans; Janus Kinase Inhibitors; Medication Therapy Management; Middle Aged; Monitoring, Immunologic; Muscle Strength; Muscle Weakness; Piperidines; Polymyositis; Pyrimidines; Pyrroles; Treatment Outcome	2019
Alterations of voluntary behavior in the course of disease progress and pharmacotherapy in mice with collagen-induced arthritis. Arthritis research & therapy, 2019, 12-12, Volume: 21, Issue:1 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Models, Animal; Disease Progression; Humans; Joints; Male; Mice, Inbred DBA; Motor Activity; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Synovitis; Temperature	2019
Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation. International journal of molecular sciences, 2020, Feb-05, Volume: 21, Issue:3 Topics: Apoptosis; Aurora Kinase B; Benzamides; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazoles; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1; Transcription, Genetic	2020
Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, Volume: 76, Issue:2 Topics: Adult; Aged; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Black or African American; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Hospitalization; Humans; Kidney Failure, Chronic; Male; Middle Aged; Mortality; Pain; Proportional Hazards Models; Prospective Studies; Pyrimidines; Pyrroles; Quality of Life; Renal Insufficiency, Chronic; Renal Replacement Therapy; White People; Young Adult	2020
Increased MAO-A Activity Promotes Progression of Pulmonary Arterial Hypertension. American journal of respiratory cell and molecular biology, 2021, Volume: 64, Issue:3 Topics: Animals; Clorgyline; Disease Models, Animal; Disease Progression; Heart Ventricles; Humans; Hypertrophy, Right Ventricular; Indoles; Monoamine Oxidase; Oxidative Stress; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyrroles; Rats; Vascular Remodeling; Vascular Stiffness; Vasodilation	2021
Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 130 Topics: Benzylamines; Cancer-Associated Fibroblasts; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Humans; Mesenchymal Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Pyrazoles; Pyrroles; Receptors, CXCR4; Signal Transduction; Transforming Growth Factor beta; Tumor Microenvironment	2020
SU6668 modulates prostate cancer progression by downregulating MTDH/AKT signaling pathway. International journal of oncology, 2017, Volume: 50, Issue:5 Topics: Angiogenesis Inhibitors; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Membrane Proteins; Neoplasm Invasiveness; Oxindoles; Propionates; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; RNA-Binding Proteins; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2	2017
Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology (Oxford, England), 2017, 08-01, Volume: 56, Issue:8 Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Withholding Treatment	2017
Clinical benefit of sunitinib in gastrointestinal stromal tumors with different exon 11 mutation genotypes. Future oncology (London, England), 2017, Volume: 13, Issue:23 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Drug Substitution; Exons; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Pyrroles; Sunitinib; Treatment Failure; Treatment Outcome	2017
Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis. Archiv der Pharmazie, 2017, Volume: 350, Issue:11 Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Inhibitory Concentration 50; Janus Kinase 3; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley	2017
Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. Urologic oncology, 2018, Volume: 36, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome	2018
Lingual metastasis as an initial presentation of renal cell carcinoma: a case report. Journal of medical case reports, 2017, Nov-07, Volume: 11, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Sunitinib; Tongue Neoplasms	2017
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation. Rheumatology international, 2018, Volume: 38, Issue:4 Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations	2018
Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female. World journal of surgical oncology, 2018, Feb-06, Volume: 16, Issue:1 Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Krukenberg Tumor; Peritoneal Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; Young Adult	2018
Tofacitinib Halts Progression of Graft Dysfunction in a Rat Model of Mixed Cellular and Humoral Rejection. Transplantation, 2018, Volume: 102, Issue:7 Topics: Animals; Chronic Disease; Complement C4b; Disease Models, Animal; Disease Progression; Graft Rejection; Graft Survival; Humans; Immunity, Cellular; Immunity, Humoral; Immunosuppressive Agents; Janus Kinase 3; Kidney; Kidney Transplantation; Male; Peptide Fragments; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred F344; Rats, Inbred Lew; Signal Transduction; Treatment Outcome	2018
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, May-23, Volume: 40, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome	2018
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia. Experimental hematology, 2018, Volume: 66 Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Case-Control Studies; Cell Line, Tumor; Chromones; Disease Progression; Dose-Response Relationship, Drug; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Myeloid Cells; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptor, PAR-1; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A	2018
Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis. PloS one, 2018, Volume: 13, Issue:11 Topics: Animals; Disease Models, Animal; Disease Progression; Endometriosis; Female; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Treatment Outcome	2018
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats. The AAPS journal, 2019, 07-24, Volume: 21, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Male; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew	2019
Statins for treating stable angina: can statins improve the plaque morphology and angina? Future cardiology, 2013, Volume: 9, Issue:2 Topics: Angina Pectoris; Angina, Stable; Atorvastatin; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plaque, Atherosclerotic; Pravastatin; Pyrroles; Ultrasonography, Interventional	2013
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult	2013
Gastrointestinal stromal tumors: diagnosis, therapy and follow-up care in Austria. Wiener medizinische Wochenschrift (1946), 2013, Volume: 163, Issue:5-6 Topics: Adult; Aftercare; Austria; Benzamides; Biopsy; Child; Combined Modality Therapy; Cooperative Behavior; Diagnosis, Differential; Diagnostic Imaging; Disease Progression; Endoscopy, Gastrointestinal; Follow-Up Studies; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Gastrointestinal Tract; Humans; Imatinib Mesylate; Indoles; Interdisciplinary Communication; Mitotic Index; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Nomograms; Palliative Care; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sunitinib	2013
Ultrasound common carotid artery segmentation based on active shape model. Computational and mathematical methods in medicine, 2013, Volume: 2013 Topics: Adventitia; Aged; Algorithms; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Computer Simulation; Disease Progression; Female; Heptanoic Acids; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Models, Anatomic; Pattern Recognition, Automated; Placebos; Pyrroles; Software; Tunica Intima; Tunica Media; Ultrasonography	2013
TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. International journal of cancer, 2013, Oct-15, Volume: 133, Issue:8 Topics: Animals; Antineoplastic Agents; Castration; Cell Line, Tumor; Cell Proliferation; Disease Progression; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paracrine Communication; Prostatic Neoplasms; Pyridines; Pyrroles; Receptors, G-Protein-Coupled; Smoothened Receptor; Tumor Microenvironment; Veratrum Alkaloids; Xenograft Model Antitumor Assays	2013
Sunitinib induces cellular senescence via p53/Dec1 activation in renal cell carcinoma cells. Cancer science, 2013, Volume: 104, Issue:8 Topics: Carcinoma, Renal Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Disease Progression; DNA Damage; G1 Phase; Humans; Indoles; Interleukins; Kidney Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-raf; Pyrroles; S Phase; Sunitinib; Tumor Necrosis Factor Decoy Receptors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2013
Monitoring plaque inflammation in atherosclerotic rabbits with an iron oxide (P904) and (18)F-FDG using a combined PET/MR scanner. Atherosclerosis, 2013, Volume: 228, Issue:2 Topics: Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Contrast Media; Dextrans; Disease Models, Animal; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Magnetic Resonance Imaging; Magnetite Nanoparticles; Plaque, Atherosclerotic; Positron-Emission Tomography; Predictive Value of Tests; Pyrroles; Rabbits; Radiography; Radiopharmaceuticals; Time Factors	2013
Transient sunitinib resistance in gastrointestinal stromal tumors. The New England journal of medicine, 2013, May-23, Volume: 368, Issue:21 Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib	2013
Focal histopathological progression of porcine experimental abdominal aortic aneurysm is mitigated by atorvastatin. International angiology : a journal of the International Union of Angiology, 2013, Volume: 32, Issue:3 Topics: Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Atorvastatin; Disease Models, Animal; Disease Progression; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Elastase; Pyrroles; Sus scrofa; Time Factors; Ultrasonography	2013
Ablation of a site of progression with stereotactic body radiation therapy extends sunitinib treatment from 14 to 22 months. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Aug-10, Volume: 31, Issue:23 Topics: Ablation Techniques; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Radiosurgery; Sunitinib	2013
[Is the same tyrosine kinase inhibitor still effective after development of brain metastases? A Case report]. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2013, Volume: 26, Issue:4 Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Male; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome	2013
Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Molecular cancer therapeutics, 2013, Volume: 12, Issue:11 Topics: Androgen Receptor Antagonists; Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Disease Progression; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptors, Androgen; Signal Transduction; Tosyl Compounds; Xenograft Model Antitumor Assays	2013
Effect of atorvastatin on atherosclerotic plaque formation and platelet activation in hypercholesterolemic rats. Canadian journal of physiology and pharmacology, 2013, Volume: 91, Issue:9 Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Atorvastatin; Biomarkers; CD40 Antigens; CD40 Ligand; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interleukin-6; Lipids; Male; P-Selectin; Plaque, Atherosclerotic; Platelet Activation; Platelet Factor 4; Pyrroles; Rats; Rats, Wistar	2013
Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. The Journal of urology, 2014, Volume: 191, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Treatment Outcome	2014
Severe exacerbation of Crohn's disease during sunitinib treatment. European journal of gastroenterology & hepatology, 2014, Volume: 26, Issue:2 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Crohn Disease; Disease Progression; Fatal Outcome; Glucocorticoids; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Prednisone; Pyrroles; Recurrence; Risk Factors; Severity of Illness Index; Sunitinib; Treatment Outcome	2014
[A case report of a well-differentiated neuroendocrine tumor in which sunitinib treatment resulted in stable disease]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:9 Topics: Antineoplastic Agents; Cell Differentiation; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Unknown Primary; Neuroendocrine Tumors; Pyrroles; Sunitinib	2013
Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy. International journal of cancer, 2014, Apr-01, Volume: 134, Issue:7 Topics: Adjuvants, Immunologic; Animals; Antigen-Presenting Cells; Cancer Vaccines; Cell Proliferation; Disease Progression; Female; Immunotherapy; Indoles; Lactalbumin; Lymph Nodes; Mice; Mice, Inbred BALB C; Pyrroles; Spleen; Sunitinib; T-Lymphocytes; Vaccination	2014
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Molecular cancer therapeutics, 2013, Volume: 12, Issue:12 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays	2013
Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2014, Volume: 122, Issue:6 Topics: Animals; Aorta, Abdominal; Atherosclerosis; Atorvastatin; Diet, High-Fat; Disease Models, Animal; Disease Progression; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Endothelin-1; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iliac Artery; Inflammation Mediators; Lipids; Male; Matrix Metalloproteinase 9; NF-kappa B; Phenylpropionates; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rabbits; RNA, Messenger	2014
Near-infrared fluorescence imaging of murine atherosclerosis using an oxidized low density lipoprotein-targeted fluorochrome. The international journal of cardiovascular imaging, 2014, Volume: 30, Issue:1 Topics: Animals; Antibodies; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Line; Cholesterol, Dietary; Disease Models, Animal; Disease Progression; Feasibility Studies; Fluorescent Dyes; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isothiocyanates; Lipoproteins, LDL; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Optical Imaging; Plaque, Atherosclerotic; Pyrroles; Time Factors	2014
Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib. Oncology reports, 2014, Volume: 31, Issue:2 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Castration; Celecoxib; Cell Survival; Cyclooxygenase 2 Inhibitors; Disease Progression; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inhibitor of Apoptosis Proteins; Interleukin-6; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Survivin; Xenograft Model Antitumor Assays	2014
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. Urologic oncology, 2014, Volume: 32, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate	2014
The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PloS one, 2014, Volume: 9, Issue:1 Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Cell Survival; CREB-Binding Protein; Curcumin; Disease Progression; Drug Synergism; E1A-Associated p300 Protein; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Histone Deacetylase Inhibitors; Neurons; Neuroprotective Agents; Nylons; Oxidative Stress; PC12 Cells; Pyrroles; Rats	2014
Mystery case: a 63-year-old man with progressive proximal pain and weakness. Neurology, 2014, Jan-28, Volume: 82, Issue:4 Topics: Atorvastatin; Blood Sedimentation; C-Reactive Protein; Creatine Kinase; Diabetes Mellitus, Type 2; Disease Progression; Electromyography; Fatigue; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Neuromuscular Junction Diseases; Pain; Pyrroles; Shoulder Pain; Tomography, X-Ray Computed	2014
The impact of pre-intervention rate of kidney function change on the assessment of CKD progression. Journal of nephrology, 2014, Volume: 27, Issue:5 Topics: Aged; Atorvastatin; Biomarkers; Creatinine; Disease Progression; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Predictive Value of Tests; Pyrroles; Randomized Controlled Trials as Topic; Recovery of Function; Renal Insufficiency, Chronic; Research Design; Retrospective Studies; Time Factors; Treatment Outcome	2014
Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. Urologic oncology, 2014, Volume: 32, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Tissue Inhibitor of Metalloproteinase-2; Treatment Outcome	2014
Effects of an angiotensin II type 1 receptor blocker on aortic valve sclerosis in a preclinical model. The Canadian journal of cardiology, 2014, Volume: 30, Issue:9 Topics: Angiotensin Receptor Antagonists; Animals; Aortic Valve; Atorvastatin; Bicuspid Aortic Valve Disease; Disease Progression; Heart Defects, Congenital; Heart Valve Diseases; Heptanoic Acids; Imidazoles; Immunohistochemistry; Male; Pyrroles; Rabbits; Random Allocation; Sclerosis; Tetrazoles	2014
[Drug resistance mechanism and new therapy strategy progression in targeted treatment of gastrointestinal stromal tumors]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2014, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Quality of Life; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib	2014
SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction. The European respiratory journal, 2014, Volume: 44, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Circadian Rhythm; Disease Models, Animal; Disease Progression; Echocardiography; Heart Ventricles; Hemodynamics; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Indoles; Lung; Male; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Systole; Telemetry; Tunica Intima; Vascular Remodeling	2014
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology, 2014, Volume: 34, Issue:9 Topics: Aged; Alleles; Atorvastatin; Cell Adhesion; Chemokine CCL19; Chemokine CCL21; Chemotaxis, Leukocyte; China; Coronary Artery Disease; Disease Progression; Ethnicity; Female; Genotype; Heptanoic Acids; Homeostasis; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipopolysaccharides; Male; Middle Aged; Monocytes; Plaque, Atherosclerotic; Polymorphism, Single Nucleotide; Pyrroles; Receptors, CCR7; Signal Transduction	2014
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell metabolism, 2014, Aug-05, Volume: 20, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous	2014
Activity and safety of sunitinib in patients with advanced radioactive iodine-refractory differentiated thyroid carcinoma in clinical practice. Endocrine, 2015, Volume: 48, Issue:2 Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Thyroglobulin; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome	2015
Relationships between the effect of sunitinib and immature blood vessels in metastatic renal cell cancer. Urologia internationalis, 2015, Volume: 94, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Vessels; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Nephrectomy; Pericytes; Platelet Endothelial Cell Adhesion Molecule-1; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome	2015
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin. European heart journal, 2015, Jan-01, Volume: 36, Issue:1 Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Disease Progression; Drug Combinations; Female; Heptanoic Acids; Mice, Transgenic; Oxazolidinones; Pyrroles; Serum Amyloid A Protein	2015
[Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy]. Kardiologiia, 2014, Volume: 54, Issue:6 Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Blood Pressure; Cardiotonic Agents; Disease Progression; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Prognosis; Pyrroles; Renal Insufficiency, Chronic; Treatment Outcome; Uric Acid	2014
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. Endocrine, 2015, Volume: 49, Issue:3 Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure	2015
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. Journal of medical economics, 2015, Volume: 18, Issue:3 Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Health Expenditures; Health Services; Humans; Imidazoles; Indazoles; Indoles; Markov Chains; Models, Econometric; Pyrroles; Quality-Adjusted Life Years; Sunitinib; United States	2015
Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment. Cancer science, 2015, Volume: 106, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progression; Endothelial Cells; Glioma; Humans; Indoles; Mice; Neovascularization, Pathologic; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Pyrroles; Rats; Rodentia; Sunitinib; Tumor Microenvironment; Vascular Endothelial Growth Factor Receptor-2	2015
Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma. European urology, 2015, Volume: 68, Issue:1 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Withholding Treatment	2015
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Targeted oncology, 2015, Volume: 10, Issue:3 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Prospective Studies; Pyrroles; Singapore; Sunitinib	2015
Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular cancer therapeutics, 2015, Volume: 14, Issue:2 Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice, SCID; Microvessels; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays	2015
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male. Urologia internationalis, 2015, Volume: 94, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome	2015
Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report. Endokrynologia Polska, 2014, Volume: 65, Issue:6 Topics: Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Indoles; Leukopenia; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib	2014
[The importance of mutational status in prognosis and therapy of GIST]. Recenti progressi in medicina, 2015, Volume: 106, Issue:1 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Phenylurea Compounds; Piperazines; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sensitivity and Specificity; Sunitinib	2015
Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib? Cancer research and treatment, 2016, Volume: 48, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Artifacts; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Reproducibility of Results; Retrospective Studies; Sunitinib; Treatment Outcome; Young Adult	2016
Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; France; Humans; Hypertension; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Pyrroles; Renin-Angiotensin System; Retrospective Studies; Risk Factors; Sunitinib; Time Factors; Treatment Outcome	2015
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget, 2015, Jun-20, Volume: 6, Issue:17 Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Arachidonic Acid; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Proliferation; Ceruletide; Cyclooxygenase 2; Disease Models, Animal; Disease Progression; Doublecortin-Like Kinases; Lipoxygenase Inhibitors; Mice; Mice, Knockout; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatitis; Protein Serine-Threonine Kinases; Pyrroles	2015
CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. European urology, 2015, Volume: 68, Issue:4 Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Disease Progression; Disease-Free Survival; Female; Haplotypes; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Netherlands; Ohio; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Spain; Sunitinib; Time Factors; Treatment Outcome	2015
Targeting cells of the myeloid lineage attenuates pain and disease progression in a prostate model of bone cancer. Pain, 2015, Volume: 156, Issue:9 Topics: Aminopyridines; Analgesics; Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Dogs; Formaldehyde; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinases; Pyrroles; Rats; Rats, Sprague-Dawley	2015
miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib. BioMed research international, 2015, Volume: 2015 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles; Sunitinib	2015
Involvement of Mast Cells in α7 Nicotinic Receptor Agonist Exacerbation of Freund's Complete Adjuvant-Induced Monoarthritis in Mice. Arthritis & rheumatology (Hoboken, N.J.), 2016, Volume: 68, Issue:2 Topics: Aconitine; Adjuvants, Immunologic; alpha7 Nicotinic Acetylcholine Receptor; Animals; Apolipoproteins E; Arthritis, Experimental; Bridged-Ring Compounds; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Freund's Adjuvant; Inflammation; Injections, Intra-Articular; Lipopolysaccharides; Male; Mast Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nicotinic Antagonists; Peptide Fragments; Pyrroles; Spiro Compounds; Xanthones	2016
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis. Oncotarget, 2016, 10-25, Volume: 7, Issue:43 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Exons; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Sunitinib; Time Factors	2016
Safety and efficacy of sunitinib for advanced non-clear cell renal cell carcinoma. Asia-Pacific journal of clinical oncology, 2015, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nevus, Spindle Cell; Prognosis; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate	2015
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1 Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indazoles; Indoles; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sulfonamides; Sunitinib; Treatment Outcome; United Kingdom	2016
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment	2016
Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma. Future oncology (London, England), 2016, Volume: 12, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease Progression; Female; Humans; Indoles; Inflammation; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome	2016
Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma. PloS one, 2016, Volume: 11, Issue:4 Topics: Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Glycolysis; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Tumor Burden	2016
Jumonji AT-rich interactive domain 1B overexpression is associated with the development and progression of glioma. International journal of molecular medicine, 2016, Volume: 38, Issue:1 Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunohistochemistry; Jumonji Domain-Containing Histone Demethylases; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Nuclear Proteins; Phosphorylation; Pyrazoles; Pyrroles; Repressor Proteins; RNA, Messenger; Smad2 Protein; Spheroids, Cellular	2016
Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours. Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:1 Topics: Antineoplastic Agents; Computer Simulation; Disease Progression; Dose-Response Relationship, Drug; Drug Monitoring; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Monte Carlo Method; Pyrroles; Sunitinib; Time Factors; Treatment Outcome	2016
Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome	2017
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib. Oncotarget, 2016, Jun-21, Volume: 7, Issue:25 Topics: Angiogenesis Inhibitors; Animals; Axitinib; Carcinoma, Renal Cell; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Pyrroles; Random Allocation; Sunitinib; Xenograft Model Antitumor Assays	2016
Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & aging, 2016, Volume: 33, Issue:9 Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Pyrroles; Registries; Retrospective Studies; Sunitinib; Time-to-Treatment	2016
Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. Clinical genitourinary cancer, 2017, Volume: 15, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Tumor Burden	2017
Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours. European radiology, 2017, Volume: 27, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Disease Progression; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hematoma; Hemoperitoneum; Humans; Imatinib Mesylate; Indoles; Intestine, Small; Male; Middle Aged; Necrosis; Peritonitis; Pyrroles; Rupture, Spontaneous; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Young Adult	2017
Sunitinib as adjuvant therapy for renal cell carcinoma. The Lancet. Oncology, 2016, Volume: 17, Issue:11 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Sunitinib; Treatment Outcome	2016
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. Angiogenesis, 2017, Volume: 20, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult	2017
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report. The American journal of case reports, 2017, Jan-03, Volume: 18 Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome	2017
The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration. Journal of neurovirology, 2017, Volume: 23, Issue:2 Topics: Acyltransferases; Animals; Antineoplastic Agents; Autophagy; Cognitive Dysfunction; Cyclin-Dependent Kinase 5; Disease Models, Animal; Disease Progression; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Indoles; Mice; Mice, Transgenic; Microtubule-Associated Proteins; Neurons; Pyrroles; Sequestosome-1 Protein; Signal Transduction; Sunitinib; tat Gene Products, Human Immunodeficiency Virus; Transgenes	2017
Surgical management of patients with progressing metastatic gastrointestinal stromal tumors receiving sunitinib treatment: A prospective cohort study. International journal of surgery (London, England), 2017, Volume: 39 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Metastasis; Postoperative Complications; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome; Young Adult	2017
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget, 2017, Jun-27, Volume: 8, Issue:26 Topics: Angiogenesis Inducing Agents; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Cluster Analysis; Cytokines; Disease Progression; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Prognosis; Pyrroles; Sunitinib; Treatment Outcome	2017
Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nature communications, 2017, 03-06, Volume: 8 Topics: Animals; Basic-Leucine Zipper Transcription Factors; Cell Differentiation; Cell Line, Tumor; Disease Progression; Female; Isoquinolines; Kaplan-Meier Estimate; Killer Cells, Natural; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mice, Transgenic; Neoplasms, Experimental; Pyridines; Pyrroles; RNA Interference; Smad3 Protein	2017
The relation between extent of coronary artery disease measured by quantitative coronary angiography and changes in lipid profile: insights from trials of atherosclerosis regression. The Journal of invasive cardiology, 2008, Volume: 20, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Disease Progression; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional	2008
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat. Naunyn-Schmiedeberg's archives of pharmacology, 2008, Volume: 378, Issue:3 Topics: Acetylcholine; Animals; Atorvastatin; Blotting, Western; Body Weight; Caspase 3; Celecoxib; Cyclooxygenase Inhibitors; Disease Progression; Drug Combinations; Hemodynamics; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Myocardium; Nitric Oxide Synthase Type III; Pulmonary Artery; Pyrazoles; Pyrroles; Rats; Rats, Wistar; Sulfonamides; Survival Analysis; Vasodilator Agents	2008
Effects of atorvastatin on progression-regression of renal injury in hyperlipidemic chickens. Histology and histopathology, 2008, Volume: 23, Issue:9 Topics: Animals; Anticholesteremic Agents; Atorvastatin; Chickens; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heptanoic Acids; Hyperlipidemias; Kidney Diseases; Kidney Glomerulus; Kidney Tubules; Lipids; Male; Pyrroles	2008
Intensive lipid intervention in the post-ENHANCE era. Mayo Clinic proceedings, 2008, Volume: 83, Issue:8 Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Coronary Disease; Diabetes Complications; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
[Systemic therapy of metastasizing renal cell carcinoma]. Der Urologe. Ausg. A, 2008, Volume: 47, Issue:10 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed	2008
Intensive lipid-lowering therapy for patients with aortic stenosis. The American journal of cardiology, 2008, Dec-01, Volume: 102, Issue:11 Topics: Aortic Valve Stenosis; Atorvastatin; Clinical Trials as Topic; Disease Progression; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2008
Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors. Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:4 Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nephrectomy; Pain; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Tomography, X-Ray Computed	2009
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model. Atherosclerosis, 2009, Volume: 205, Issue:1 Topics: Acetates; Animals; Atherosclerosis; Atorvastatin; Carotid Arteries; Catheterization; Chemokine CCL2; Cyclopropanes; Diet, Atherogenic; Disease Progression; Heptanoic Acids; Immunohistochemistry; Leukotriene Antagonists; Lipids; Male; Pyrroles; Quinolines; Rabbits; Random Allocation; Sulfides	2009
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. European urology, 2009, Volume: 56, Issue:1 Topics: Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Pancreatic Neoplasms; Pyrroles; Salvage Therapy; Sunitinib	2009
Effect of lipid-lowering therapy on the progression of intracranial arterial stenosis. Journal of neurology, 2009, Volume: 256, Issue:2 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cerebral Arteries; Constriction, Pathologic; Disease Progression; Female; Heptanoic Acids; Humans; Hyperlipidemias; Infarction, Middle Cerebral Artery; Intracranial Arteriosclerosis; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyrroles; Secondary Prevention; Sex Distribution; Stroke; Treatment Outcome; Vertebrobasilar Insufficiency	2009
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology, 2009, Volume: 76, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome	2009
Hypofractionated radiotherapy with concomitant sunitinib - is there a radiosensitizing effect? The Canadian journal of urology, 2009, Volume: 16, Issue:2 Topics: Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Dose Fractionation, Radiation; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pleural Neoplasms; Pyrroles; Radiation-Sensitizing Agents; Sunitinib	2009
Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas. British journal of cancer, 2009, May-19, Volume: 100, Issue:10 Topics: Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Disease Progression; HT29 Cells; Humans; Indoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Oxindoles; Propionates; Pyrroles; Receptor Protein-Tyrosine Kinases; Stromal Cells; Up-Regulation; Xenograft Model Antitumor Assays	2009
'Sunitinib withdrawal phenomenon' or spontaneous regression in renal cell cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Remission Induction; Remission, Spontaneous; Sunitinib	2009
Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-01, Volume: 15, Issue:11 Topics: Animals; Anorexia; Diarrhea; Disease Progression; Dog Diseases; Dogs; Female; Indoles; Male; Mast-Cell Sarcoma; Neoplasm Recurrence, Local; Pyrroles; Random Allocation; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Vomiting	2009
Re: Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. A. A. Thomas, B. I. Rini, B. R. Lane, J. Garcia, R. Dreicer, E. A. Klein, A. C. Novick And S. C. Campbell. J Urol 2009; 181: 518-523. The Journal of urology, 2009, Volume: 182, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Pyrroles; Sunitinib	2009
Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Modern rheumatology, 2009, Volume: 19, Issue:5 Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Cell Count; Cell Separation; Disease Progression; E-Selectin; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Flow Cytometry; Fluorescent Antibody Technique; Health Status; Heptanoic Acids; Humans; Immunoprecipitation; Middle Aged; Prospective Studies; Pyrroles; Raynaud Disease; Scleroderma, Systemic; Severity of Illness Index; Stem Cells; Treatment Outcome; Vascular Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A	2009
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome	2010
Biomarkers in GIST: partly ready for prime-time use. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18 Topics: Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Indoles; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Sunitinib; Time Factors	2009
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma. American journal of clinical oncology, 2010, Volume: 33, Issue:3 Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2010
Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology, 2009, Sep-29, Volume: 73, Issue:13 Topics: Adjuvants, Immunologic; Atorvastatin; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon beta-1a; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Pyrroles	2009
Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology (Baltimore, Md.), 2010, Volume: 51, Issue:2 Topics: Carcinoma, Hepatocellular; Connective Tissue Growth Factor; Disease Progression; Down-Regulation; Humans; Liver Neoplasms; Pyrazoles; Pyrroles; Transforming Growth Factor beta; Tumor Cells, Cultured	2010
Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. International immunopharmacology, 2010, Volume: 10, Issue:1 Topics: Animals; Antigens, CD; Antineoplastic Agents; Disease Progression; Female; Immune Evasion; Indoles; Mammary Neoplasms, Animal; Mice; Mice, Inbred Strains; Mice, Transgenic; Myeloid Cells; Pyrroles; Receptor, ErbB-2; Sunitinib; T-Lymphocytes, Regulatory	2010
Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. British journal of cancer, 2009, Dec-01, Volume: 101, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain-Derived Neurotrophic Factor; Carcinoma, Renal Cell; Cytokines; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Humans; Indoles; Kidney Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Sunitinib; Survival Rate; Tumor Necrosis Factor-alpha	2009
Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Canadian journal of physiology and pharmacology, 2009, Volume: 87, Issue:11 Topics: Aged; Aged, 80 and over; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apoptosis Regulatory Proteins; Atorvastatin; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Disease Progression; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2009
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer biology & therapy, 2010, Volume: 9, Issue:1 Topics: Antineoplastic Agents; Arteries; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney; Kidney Neoplasms; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Tumor Burden	2010
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1 Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2010
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:1 Topics: Androgens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Blotting, Western; Celecoxib; Cell Proliferation; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Pyrazoles; Pyrroles; Sulfonamides; Xenograft Model Antitumor Assays	2010
Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clinical & experimental metastasis, 2010, Volume: 27, Issue:1 Topics: Animals; Cell Line, Tumor; Cell Movement; Disease Progression; Humans; Melanoma; Mice; Mice, SCID; Neoplasm Metastasis; Pyrroles; Quinazolines; Receptor, PAR-1; Skin Neoplasms	2010
Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:4 Topics: Adult; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Pyrroles; Sunitinib; Time Factors; Tomography, X-Ray Computed; Vena Cava, Inferior; Venous Thrombosis	2010
[Sunitinib in clinical practice: the expanded access program for metastatic renal cell carcinoma]. Onkologie, 2010, Volume: 33 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Approval; Drug Delivery Systems; Drugs, Investigational; Germany; Humans; Indoles; Kidney Neoplasms; Pyrroles; Sunitinib; Survival Rate	2010
[Monitoring of metastatic renal cell carcinoma--standards and challenges]. Onkologie, 2010, Volume: 33 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drug Monitoring; Drugs, Investigational; Follow-Up Studies; Germany; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Pyrroles; Sunitinib; Survival Rate; Tomography, X-Ray Computed	2010
Combined hyperlipidemia in patients with lysinuric protein intolerance. Journal of inherited metabolic disease, 2010, Volume: 33 Suppl 3 Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult	2010
Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2010, Volume: 39, Issue:5 Topics: Aged; Aorta; Aortic Aneurysm, Abdominal; Atorvastatin; Biomarkers; Cathepsin A; Cathepsin B; Chi-Square Distribution; Cohort Studies; Disease Progression; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interferon-gamma; Interleukins; Lymphotoxin-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Netherlands; Pravastatin; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Tumor Necrosis Factor-alpha; Vascular Surgical Procedures	2010
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome	2010
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urologie, 2010, Volume: 41, Issue:3 Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib	2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR. American journal of roentgenology, 2010, Volume: 194, Issue:6 Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2010
Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular cancer therapeutics, 2010, Volume: 9, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Epithelium; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Mesoderm; Mice; Mice, Nude; Microvessels; Pericytes; Phenotype; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays	2010
Abscess formation mimicking disease progression, in a patient with metastatic renal cell carcinoma during sunitinib treatment. World journal of surgical oncology, 2010, May-28, Volume: 8 Topics: Abdominal Abscess; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib	2010
Downsizing treatment with tyrosine kinase inhibitors in patients with advanced gastrointestinal stromal tumors improved resectability. World journal of surgery, 2010, Volume: 34, Issue:9 Topics: Aged; Benzamides; Chemotherapy, Adjuvant; Disease Progression; DNA Mutational Analysis; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sequence Deletion; Sunitinib; Survival Analysis; Tomography, X-Ray Computed	2010
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A	2011
Celecoxib combined with atorvastatin prevents progression of atherosclerosis. The Journal of surgical research, 2010, Volume: 163, Issue:2 Topics: Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Celecoxib; Chemokine CCL2; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Disease Progression; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Pyrazoles; Pyrroles; Sulfonamides; Vascular Cell Adhesion Molecule-1	2010
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:2 Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Pyrroles; Sunitinib; Survival Analysis	2011
Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma. Endocrine journal, 2010, Volume: 57, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Atrophy; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Hyperthyroidism; Hypothyroidism; Indoles; Japan; Male; Middle Aged; Organ Size; Protein Kinase Inhibitors; Pyrroles; Regional Blood Flow; Sunitinib; Thyroid Gland; Thyroiditis; Thyrotoxicosis	2010
A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System. Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:4 Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cytokines; Disease Progression; Disease-Free Survival; Drug Costs; Drug Resistance, Neoplasm; Female; Health Care Costs; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Palliative Care; Protein Kinase Inhibitors; Pyrroles; Quality-Adjusted Life Years; Spain; Sunitinib	2010
A novel primary KIT exon 9 single nucleotide substitution c.1427G>T (p.Ser476Ile) in a gastrointestinal stromal tumor. Virchows Archiv : an international journal of pathology, 2010, Volume: 457, Issue:5 Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Combined Modality Therapy; Digestive System Surgical Procedures; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Molecular Sequence Data; Peritoneal Neoplasms; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib	2010
Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:4 Topics: Bone Neoplasms; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Pyrroles; Retrospective Studies; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2011
Progression of intramedullary metastasis during perioperative cessation of sunitinib. Nature reviews. Urology, 2010, Volume: 7, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Pyrroles; Spinal Neoplasms; Sunitinib	2010
Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer research, 2010, Volume: 30, Issue:9 Topics: Animals; Antineoplastic Agents; Disease Progression; Female; Humans; Immunohistochemistry; Indoles; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays	2010
The impact of tumor burden characteristics in patients with metastatic renal cell carcinoma treated with sunitinib. Cancer, 2011, Mar-15, Volume: 117, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Tumor Burden; Young Adult	2011
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology, 2010, Volume: 79, Issue:1-2 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome	2010
Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma. Chemotherapy, 2010, Volume: 56, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Renal Dialysis; Retrospective Studies; Sunitinib	2010
Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. Investigational new drugs, 2012, Volume: 30, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Chi-Square Distribution; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Exons; Female; Gastrointestinal Stromal Tumors; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Phenotype; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sunitinib; Time Factors; Treatment Failure	2012
Cyclooxygenase-2 expression in gastrointestinal stromal tumours. Asian Pacific journal of cancer prevention : APJCP, 2010, Volume: 11, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chi-Square Distribution; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Male; Middle Aged; Mitosis; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Tumor Burden	2010
Response of renal lesions during systemic treatment with sunitinib in patients with metastatic renal cell carcinoma: a single center experience with 14 patients. World journal of urology, 2011, Volume: 29, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Palliative Care; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2011
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma. BJU international, 2011, Volume: 108, Issue:5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States	2011
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors	2012
Promising advances in the treatment of malignant pancreatic endocrine tumors. The New England journal of medicine, 2011, Feb-10, Volume: 364, Issue:6 Topics: Antineoplastic Agents; Disease Progression; Everolimus; Humans; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quality of Life; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases	2011
A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha. Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Ventricular Function, Left	2011
Mutational spectrum and therapy response of metastasized GIST in Central Switzerland - a population-based study. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Disease Progression; DNA Mutational Analysis; DNA Primers; Exons; Female; Gastrointestinal Stromal Tumors; Genetics, Population; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Switzerland	2011
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World journal of urology, 2011, Volume: 29, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome	2011
Combination therapy of candesartan with statin inhibits progression of atherosclerosis more than statin alone in patients with coronary artery disease. Coronary artery disease, 2011, Volume: 22, Issue:5 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Benzimidazoles; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Cholesterol; Coronary Artery Disease; Dinoprost; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Longitudinal Studies; Male; Matrix Metalloproteinase 9; Middle Aged; Pyrroles; Tetrazoles; Tomography, X-Ray Computed	2011
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors. World journal of urology, 2013, Volume: 31, Issue:4 Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome	2013
Treatment of gastrointestinal stromal tumor after imatinib and sunitinib. Current opinion in oncology, 2011, Volume: 23, Issue:4 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure	2011
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies]. Der Urologe. Ausg. A, 2011, Volume: 50, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases	2011
Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:8 Topics: Adenoma; Animals; Anticarcinogenic Agents; Biological Assay; Biomarkers, Tumor; Disease Models, Animal; Disease Progression; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Models, Chemical; Pyrroles	2011
[Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:5 Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Recurrence; Sunitinib	2011
Bilateral carotid atherosclerosis: an inevitable consequence of homozygous familial hypercholesterolemia. The Journal of heart valve disease, 2011, Volume: 20, Issue:3 Topics: Angioplasty; Atorvastatin; Carotid Stenosis; Disease Progression; Genetic Predisposition to Disease; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver Transplantation; Phenotype; Pyrroles; Radiography; Severity of Illness Index; Stents; Time Factors; Treatment Outcome; Treatment Refusal	2011
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma. Investigational new drugs, 2012, Volume: 30, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome	2012
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urologie, 2011, Volume: 42, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A	2011
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PloS one, 2011, Volume: 6, Issue:7 Topics: Animals; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Disease Progression; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Glucose; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Nude; Microdissection; Microvessels; Molecular Targeted Therapy; Necrosis; Ovarian Neoplasms; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2011
Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines. Kidney & blood pressure research, 2012, Volume: 35, Issue:1 Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Humans; Hypertension; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Predictive Value of Tests; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2012
Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer. Acta oncologica (Stockholm, Sweden), 2011, Volume: 50, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Administration, Oral; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome; Withholding Treatment	2011
Treatment of an adrenomyeloneuropathy patient with Lorenzo's oil and supplementation with docosahexaenoic acid--a case report. Lipids in health and disease, 2011, Aug-26, Volume: 10 Topics: Adrenoleukodystrophy; Adult; Anticholesteremic Agents; Atorvastatin; Combined Modality Therapy; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Erucic Acids; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Pyrroles; Treatment Outcome; Triolein	2011
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Count; Disease Progression; Disease-Free Survival; Epidemiologic Methods; Female; Humans; Indoles; Kidney Neoplasms; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pyrroles; Sunitinib; Young Adult	2012
Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma. International immunopharmacology, 2011, Volume: 11, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Mitosis; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survivin; Treatment Outcome	2011
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PloS one, 2011, Volume: 6, Issue:12 Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cell Movement; Cholesterol; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Transgenic; Models, Biological; Monocytes; Promoter Regions, Genetic; Pyrroles; Receptors, CCR7; Response Elements; Sterol Regulatory Element Binding Proteins; Sterols	2011
Sunitinib inhibits the phosphorylation of platelet-derived growth factor receptor β in the skin of mice with scleroderma-like features and prevents the development of the disease. Arthritis and rheumatism, 2012, Volume: 64, Issue:6 Topics: Animals; Cell Proliferation; Disease Models, Animal; Disease Progression; Fibroblasts; Indoles; Mice; Phosphorylation; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Scleroderma, Systemic; Skin; Sunitinib	2012
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. International journal of cancer, 2012, Oct-15, Volume: 131, Issue:8 Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Disease Progression; Fluorescent Antibody Technique; Heptanoic Acids; Humans; Immunoenzyme Techniques; Integrases; Interferon-Stimulated Gene Factor 3, gamma Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured	2012
[Symptomatic coronary heart disease. Impressive plaque reduction with high dose statins]. MMW Fortschritte der Medizin, 2011, Dec-08, Volume: 153, Issue:49-50 Topics: Atorvastatin; Clinical Trials as Topic; Coronary Artery Disease; Disease Progression; Dose-Response Relationship, Drug; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Survival Rate	2011
The addition of Sunitinib to radiation delays tumor growth in a murine model of glioblastoma. Neurological research, 2012, Volume: 34, Issue:3 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Disease Models, Animal; Disease Progression; Glioblastoma; Indoles; Mice; Mice, Transgenic; Pyrroles; Radiation Dosage; Sunitinib	2012
[Metastatic apocrine adenocarcinoma of the penis: cytostatic therapy]. Aktuelle Urologie, 2012, Volume: 43, Issue:3 Topics: Adult; Antineoplastic Agents; Apocrine Glands; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Humans; Indoles; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Multimodal Imaging; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Positron-Emission Tomography; Protein-Tyrosine Kinases; Pyrroles; Sunitinib; Sweat Gland Neoplasms; Tomography, X-Ray Computed; Tumor Burden	2012
Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World journal of surgical oncology, 2012, Jun-15, Volume: 10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Disease Progression; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Rate; Young Adult	2012
Sunitinib malate in solitary fibrous tumor (SFT). Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12 Topics: Adult; Aged; Angiogenesis Inhibitors; Antigens, CD34; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Solitary Fibrous Tumors; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2	2012
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib	2012
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. Journal of medical economics, 2012, Volume: 15 Suppl 1 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Disease Progression; Drug Costs; Everolimus; Humans; Indoles; Markov Chains; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sunitinib; Survival Analysis; United States	2012
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. International journal of colorectal disease, 2013, Volume: 28, Issue:6 Topics: Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fluorouracil; Humans; Indoles; MicroRNAs; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome	2013
Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. JACC. Cardiovascular imaging, 2012, Volume: 5, Issue:8 Topics: Animals; Apolipoproteins B; Atorvastatin; Disease Progression; Fluorodeoxyglucose F18; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Liver X Receptors; Macrophages; Multimodal Imaging; Orphan Nuclear Receptors; Plaque, Atherosclerotic; Positron-Emission Tomography; Pyrroles; Rabbits; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome	2012
Targeting neuroendocrine tumor: mixing standard options with novel therapies. Targeted oncology, 2012, Volume: 7, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarbazine; Disease Progression; Drug Resistance, Neoplasm; Humans; Indoles; Medical Oncology; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sunitinib; Temozolomide; Treatment Outcome	2012
Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. European review for medical and pharmacological sciences, 2012, Volume: 16, Issue:7 Topics: Aged; Angiogenesis Inhibitors; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Fatal Outcome; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pyrroles; Risk Factors; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2012
Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. British journal of cancer, 2012, Oct-09, Volume: 107, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Apoptosis; Biomarkers, Tumor; Disease Progression; Endothelial Cells; Female; Humans; Indoles; Keratin-18; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prospective Studies; Pyrroles; Sunitinib; Treatment Failure	2012
Vasa vasorum and plaque progression, and responses to atorvastatin in a rabbit model of atherosclerosis: contrast-enhanced ultrasound imaging and intravascular ultrasound study. Heart (British Cardiac Society), 2013, Volume: 99, Issue:1 Topics: Animals; Atorvastatin; Carotid Artery Diseases; Carotid Artery, Common; Cell Proliferation; Contrast Media; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Image Enhancement; Male; Plaque, Atherosclerotic; Pyrroles; Rabbits; Ultrasonography, Interventional; Vasa Vasorum	2013
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult	2013
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology, 2013, Volume: 84, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; Follow-Up Studies; Hepatocyte Growth Factor; Humans; Indoles; Interleukin-6; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor A	2013
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. Heart and vessels, 2014, Volume: 29, Issue:1 Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Disease Progression; Dyslipidemias; Female; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrroles; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome	2014
A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis. Acta bio-medica : Atenei Parmensis, 2012, Volume: 83, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome	2012
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less? Circulation, 2002, Oct-15, Volume: 106, Issue:16 Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography	2002
Colorectal cancer: targeting metastasis and angiogenesis. Clinical colorectal cancer, 2002, Volume: 1, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Colorectal Neoplasms; Disease Progression; Extracellular Matrix; Humans; Indoles; Matrix Metalloproteinases; Neoplasm Metastasis; Neovascularization, Pathologic; Pyrroles	2002
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography. The American journal of cardiology, 2003, Jan-01, Volume: 91, Issue:1 Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome	2003
SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Molecular cancer therapeutics, 2003, Volume: 2, Issue:7 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Differentiation; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Indoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microcirculation; Neovascularization, Pathologic; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Up-Regulation; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2	2003
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go? Harvard heart letter : from Harvard Medical School, 2004, Volume: 14, Issue:6 Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke	2004
Colestimide co-administered with atorvastatin attenuates the progression of vascular calcification in haemodialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2004, Volume: 19, Issue:8 Topics: Anion Exchange Resins; Anticholesteremic Agents; Atorvastatin; Blood Vessels; Calcinosis; Disease Progression; Drug Therapy, Combination; Epichlorohydrin; Heptanoic Acids; Humans; Imidazoles; Prospective Studies; Pyrroles; Renal Dialysis; Resins, Synthetic	2004
Plaque regression--a new target for antiatherosclerotic therapy. American heart journal, 2005, Volume: 149, Issue:3 Topics: Angioplasty, Balloon, Coronary; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Premedication; Pyrroles; Radiography; Remission Induction; Risk Reduction Behavior; Simvastatin; Ultrasonography	2005
Effects of Atorvastatin on Th polarization in patients with acute myocardial infarction. European journal of heart failure, 2005, Volume: 7, Issue:7 Topics: Atorvastatin; Cells, Cultured; Disease Progression; Female; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lymphocyte Activation; Male; Middle Aged; Myocardial Infarction; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Helper-Inducer	2005
Statins for aortic stenosis. The New England journal of medicine, 2005, Jun-09, Volume: 352, Issue:23 Topics: Aortic Valve Stenosis; Atorvastatin; Calcinosis; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles	2005
Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. The Prostate, 2006, Feb-01, Volume: 66, Issue:2 Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Disease Progression; Doxorubicin; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Receptors, LHRH; RNA, Messenger; Transplantation, Heterologous; Triptorelin Pamoate	2006
Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology, 2005, Volume: 66, Issue:6 Topics: Aged; Atorvastatin; Brachytherapy; Disease Progression; Disease-Free Survival; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prostatic Neoplasms; Pyrroles	2005
Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2006, Volume: 47, Issue:1 Topics: Adolescent; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Atorvastatin; Biopsy, Needle; Disease Progression; Follow-Up Studies; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunoglobulin A; Immunoglobulin M; Immunosuppressive Agents; Kidney Glomerulus; Lupus Erythematosus, Systemic; Lupus Nephritis; Male; Organelles; Plasma Exchange; Pyrroles; Sclerosis; Severity of Illness Index; Software Design	2006
Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. International journal of cancer, 2006, Jul-15, Volume: 119, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cricetinae; Disease Progression; Indoles; Integrin alphaV; Male; Mesocricetus; Microcirculation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrroles; Vascular Endothelial Growth Factor Receptor-2	2006
Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Apr-15, Volume: 12, Issue:8 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indoles; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sunitinib; Tumor Cells, Cultured	2006
Licofelone reduces progression of structural changes in a canine model of osteoarthritis under curative conditions: effect on protease expression and activity. The Journal of rheumatology, 2006, Volume: 33, Issue:6 Topics: Acetates; Animals; Anterior Cruciate Ligament; Cartilage, Articular; Collagenases; Disease Models, Animal; Disease Progression; Dogs; Enzyme Inhibitors; Metalloproteases; Osteoarthritis, Knee; Pyrroles; Stifle	2006
Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-20, Volume: 24, Issue:15 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Doxorubicin; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sunitinib; Survival Analysis; Treatment Outcome	2006
Letter by Schmermund and Erbel regarding article, "Coronary artery calcium: should we rely on this surrogate marker?". Circulation, 2006, Aug-01, Volume: 114, Issue:5 Topics: Anticholesteremic Agents; Atorvastatin; Calcinosis; Calcium; Coronary Artery Disease; Coronary Vessels; Disease Progression; Heptanoic Acids; Humans; Predictive Value of Tests; Prognosis; Pyrroles; Risk Factors	2006
A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 2006, Volume: 22, Issue:4 Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Capillary Permeability; Choroidal Neovascularization; Disease Models, Animal; Disease Progression; Female; Fluorescein; Fluorescein Angiography; Indoles; Mice; Mice, Inbred C57BL; Pyrroles; Sunitinib; Vascular Endothelial Growth Factor Receptor-2	2006
Re-elevation of high-sensitivity C-reactive protein but not the von Willebrand Factor after withdrawing atorvastatin therapy in patients with unstable angina undergoing coronary artery stenting. International heart journal, 2006, Volume: 47, Issue:4 Topics: Angina, Unstable; Atorvastatin; Biomarkers; C-Reactive Protein; Coronary Angiography; Coronary Artery Bypass; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoenzyme Techniques; Male; Middle Aged; Nephelometry and Turbidimetry; Prognosis; Pyrroles; Retrospective Studies; Severity of Illness Index; Stents; Time Factors; von Willebrand Factor	2006
New therapeutic options for renal cell carcinoma. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib	2006
B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood, 2007, Feb-01, Volume: 109, Issue:3 Topics: Bryostatins; Calcium; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Mesylates; Protein Kinase C; Protein Kinase C beta; Pyrroles; Receptors, Antigen, B-Cell; Signal Transduction	2007
[Sunitinib for gastrointestinal stromal cell tumors and advanced renal cell carcinoma]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:10 Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib	2006
Current and future management of GIST. Clinical advances in hematology & oncology : H&O, 2006, Volume: 4, Issue:8 Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome	2006
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (Baltimore, Md.), 2006, Volume: 44, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain	2006
Sunitinib malate. Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Disease Progression; Endothelium, Vascular; Enzyme Inhibitors; Gastrointestinal Stromal Tumors; Humans; Indoles; Leukemia, Myeloid; Lung Neoplasms; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sunitinib	2007
Effects of vascular endothelial growth factor receptor inhibitor SU5416 and prostacyclin on murine lung metastasis. Anti-cancer drugs, 2007, Volume: 18, Issue:3 Topics: Animals; Carcinoma, Lewis Lung; Cell Adhesion; Cells, Cultured; Disease Progression; Epoprostenol; Indoles; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasm Transplantation; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Splenic Neoplasms	2007
[Effects of atorvastatin on hyperlipidemia in kidney disease patients]. Nihon Jinzo Gakkai shi, 2007, Volume: 49, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Diseases; Male; Middle Aged; Pyrroles; Renal Dialysis	2007
Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circulation research, 2007, Mar-30, Volume: 100, Issue:6 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Disease Progression; Endothelin A Receptor Antagonists; Hypertension, Pulmonary; Hypoxia; Indoles; Intracellular Signaling Peptides and Proteins; Male; Myosin-Light-Chain Phosphatase; Organ Culture Techniques; Peptides, Cyclic; Phosphorylation; Protein Serine-Threonine Kinases; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; rho-Associated Kinases; Vascular Endothelial Growth Factor Receptor-2; Vasoconstriction; Vasodilator Agents	2007
Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2007, Volume: 22, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cohort Studies; Disease Progression; Dyslipidemias; Female; Heptanoic Acids; Humans; Kidney Failure, Chronic; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Pyrroles	2007
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination]. Praxis, 2007, May-02, Volume: 96, Issue:18 Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed	2007
Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. The oncologist, 2007, Volume: 12, Issue:6 Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Piperazines; Pyrimidines; Pyrroles; Sunitinib	2007
Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study. American journal of physiology. Lung cellular and molecular physiology, 2007, Volume: 293, Issue:4 Topics: Animals; Atorvastatin; Blood Pressure; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Echocardiography; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Male; Monocrotaline; Phosphorylation; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Simvastatin; Sirolimus	2007
Surgical resection of residual disease in initially inoperable imatinib-resistant/intolerant gastrointestinal stromal tumor treated with sunitinib. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Pyrroles; Sunitinib; Treatment Outcome	2009
Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis. Pathophysiology of haemostasis and thrombosis, 2007, Volume: 36, Issue:1 Topics: Acetamides; Acetates; Animals; Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Catheterization; Cholesterol; Disease Progression; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Magnetic Resonance Imaging; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Pyrroles; Rabbits; Random Allocation; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids	2007
Atorvastatin slows the progression of cardiac remodeling in mice with pressure overload and inhibits epidermal growth factor receptor activation. Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:2 Topics: Animals; Atorvastatin; Cardiomegaly; Disease Progression; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Heart Failure; Heparin-binding EGF-like Growth Factor; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Natriuretic Peptide, Brain; Phosphorylation; Pyrroles; Ventricular Function, Left	2008
A dopamine receptor antagonist L-745,870 suppresses microglia activation in spinal cord and mitigates the progression in ALS model mice. Experimental neurology, 2008, Volume: 211, Issue:2 Topics: Amyotrophic Lateral Sclerosis; Animals; Cell Movement; Disease Models, Animal; Disease Progression; Dopamine Antagonists; Female; Humans; Male; Mice; Mice, Congenic; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Pyridines; Pyrroles; Spinal Cord	2008
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia. The American journal of cardiology, 1999, Dec-01, Volume: 84, Issue:11 Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E	1999
Clinical strategy for the development of angiogenesis inhibitors. The oncologist, 2000, Volume: 5 Suppl 1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Decision Making; Disease Progression; Drug Evaluation; Drug Resistance, Neoplasm; Drugs, Investigational; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Lymphokines; Protein Isoforms; Protein-Tyrosine Kinases; Pyrroles; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2000
Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice. Arteriosclerosis, thrombosis, and vascular biology, 2001, Volume: 21, Issue:10 Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcinosis; Cholesterol; Diet, Atherogenic; Disease Progression; Female; Heptanoic Acids; Male; Mice; Mice, Transgenic; Pyrroles; Reproducibility of Results; Spectrum Analysis, Raman; Treatment Outcome	2001
Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation, 2001, Oct-30, Volume: 104, Issue:18 Topics: Aged; Aortic Valve Stenosis; Atorvastatin; Calcinosis; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; Echocardiography; Electrocardiography; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Multivariate Analysis; Pravastatin; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Treatment Outcome; Triglycerides; Vascular Patency	2001